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4Executive summary
The challenge of communicable disease
Over the second half of the twentieth century, the world has seen enormous health
improvements.  However, developing countries have benefited unequally from health
gains, with many, especially in sub-Saharan Africa (SSA), continuing to experience
high mortality.  Children bear a major burden of ill health, with infectious and parasitic
diseases the main killers.  Adults experience substantial premature mortality. Within
countries, poorer groups have considerably worse health than the better off.  Analysis of
avoidable mortality highlights the importance of communicable disease, which
represents around 90% of all avoidable mortality in almost all age/sex groups.  The
benefits of research mean that tools and approaches now exist to address the great
majority of the burden of communicable disease, most notably malaria, TB, and
HIV/AIDS, as well as vaccine preventable diseases.  However, large numbers of people
do not have effective access to prevention and treatment, and as a result die.
The paper focuses on three opportunities:
• Malaria control
• HIV/AIDS control
• Strengthening basic health services.
This categorisation has been chosen largely because malaria and HIV/AIDS are major
causes of disease burden and economic losses; cost-effective interventions are known to
exist for their control; there is recent literature which can be drawn on to estimate costs
and benefits; and these diseases are currently the focus of world attention.  Basic health
services have been chosen as the third opportunity since they address a major part of the
disease burden, and represent explicitly the infrastructure that needs to be in place for
people’s main health needs to be met.
The economic benefits of improved health
The relationship between illness and income is complex.  Effects are felt both directly
(through the immediate impact of ill health on productive activities) and indirectly, via
the effects of illness on fertility, morbidity, mortality and intellectual capacity, and
hence on the labour force size, composition and quality, and on the capacity of countries
to engage in the global economy.  Empirical studies of the relationship between disease
and economic outcomes fall into two categories: microeconomic and macroeconomic.
The former study the link between disease/ill health at household or individual level,
usually documenting the costs imposed by disease on households but not explicitly the
benefits of disease control, and categorising costs as direct and indirect.  Such estimates
are likely to underestimate the true economic impact of a disease, since they neglect the
impact of coping strategies and the broader, dynamic consequences of disease for the
economy as a whole.  In contrast, macroeconomic studies assess the influence of a
disease on national income in cross-country comparisons.  In principle they are better
able than microeconomic studies to reflect the wide-ranging and dynamic implications
of ill health, but raise concerns as to the extent to which other influences on economic
growth are adequately allowed for.   Again such studies usually document the cost of
disease, but only by implication the benefits of disease reduction.
5The most abundant literature is that on the cost-effectiveness of interventions,
comparing intervention cost with benefits expressed in terms of health outcomes.
Systematic approaches have recently been applied to the synthesis of both
epidemiological studies and economic studies, making judgements on the quality of
evidence, and facilitating conclusions on both health outcomes of interventions and
cost-effectiveness.  However, using these studies to evaluate the efficiency of health
interventions in units that are comparable across economic sectors requires placing a
monetary value on human life.
Given the limitations of the literature in terms both of quantity and quality, and the need
to be comprehensive and consistent, estimates of costs and benefits were where possible
calculated by the authors based on the literature rather than limiting the paper only to
costs and benefits actually provided in the literature.  Several different approaches were
adopted.  For the two diseases (malaria and HIV), evidence was drawn from three
different sources:
• Studies of the macroeconomic impact of the disease
• Studies of the cost-effectiveness of interventions
• Evidence of the costs and health benefits of large scale country programmes.
For basic health services, evidence was drawn from two different sources:
• Regression analyses that measured the efficiency of health expenditure in generating
health outcomes
• The costs and health benefits of a package of interventions recommended in the
1993 World Development Report.
Where possible, costs and benefits were summarised as both annualised net benefits
(ANB) adjusted for Purchasing Power Parity and benefit cost ratios (BCR).  A year of
life lost was valued at 2003 per capita Gross National Income (GNI) (the ceiling ratio),
and a discount rate (DCR) of 3% applied. In sensitivity analyses, the DCR was set at 6%
and the ceiling ratio at the mean GNI for low and middle income countries of Int$3,830.
Control of malaria
Major reductions in the malaria burden and its eradication from temperate parts of the
world gave reason for optimism in the mid twentieth century.  However, in the 1980’s,
commitment to programmes waned and resistance to medicines and insecticides
increased.  With the increased use of new combination drugs and a greater international
commitment to financing malaria control, there is again reason to believe that the
burden of malaria can be substantially reduced.  SSA experiences over 90% of the
global burden of malaria; malaria causes around 20% of the mortality of children under
5; and it is the most important single infectious agent causing death in young children.
Cost-benefit estimates were therefore made for SSA, drawing on macroeconomic
studies; on cost-effectiveness studies of insecticide-treated mosquito nets, intermittent
presumptive treatment of pregnant women (IPTp), and combination therapy (ACT); and
evidence from recent successful malaria control efforts in the KwaZulu Natal province
of South Africa.  Based on estimates from macroeconomic models, we predicted that
the ANB of eliminating 50% of malaria between 2002-15 would be Int$11-43 bn, with
BCRs of 1.9-4.7. For the package of malaria control measures these were Int$47.4 bn
and 27.  The ANB of the successful South African malaria control programme was
Int$9m, and it was cost saving.
6 Control of HIV/AIDS
The HIV/AIDS pandemic is devastating the economies of many low- and middle-
income countries.  Current estimates are that more than 22m people have already died,
34-46m are currently living with HIV/AIDS, and 5.3m new infections occur each year.
The scale of the problem is such that it is considered a development issue and global
security threat.  The costs and benefits of approaches to addressing the epidemic were
estimated, drawing on four different sources of information: a macroeconomic model of
the gains to prevention in several north African and Middle Eastern countries at the
‘nascent’ stage of the epidemic; the costs and benefits of successful control in Thailand,
at the ‘concentrated’ stage of the epidemic; evidence on the cost-effectiveness of a
number of specific interventions in Africa; and estimates of the cost and health impact
of the UNGASS global programme.  For the group of North African/Middle Eastern
countries, intervening now was estimated to save 15-30% of 2000 GNP by 2005.  In
Thailand, the ANB of the AIDS control was Int$3.5 bn and BCR 15.  BCRs of
individual interventions were highly variable but generally exceeded 2, with condom
distribution and blood safety having BCRs of 466.  The UNGASS package had ANB of
Int$359.4 bn and BCR of 50.
Basic health services
The great majority of health interventions depend for successful and sustained
implementation on an infrastructure of basic health services, consisting of community
based services, health centres, and local hospitals.   These can address much of the
burden of ill health including that from maternal and neonatal conditions, childhood
illnesses such as diarrhoea, ARI and vaccine preventable diseases, and malaria, TB and
HIV/AIDS.  Over the last decade recommendations have been made on a package of
priority interventions to be delivered at this level.  We estimated the costs and benefits
of scaling up basic health services drawing on firstly evidence for HIPC countries of the
relationship between health expenditure and health gains and the necessary increase in
public spending to reach the MDG child mortality target; and secondly estimates of the
costs and health benefits of the package of interventions recommended in the 1993
World Development Report.  The first approach gives ANB of Int$50.0 bn and BCR 3.9
(though benefits for children only are included).  The 1993 WDR package gives ANB
of Int$534.1 bn and BCR of 2.6.
Conclusions
All sources of data used have severe shortcomings, which must inform the interpretation
of the costs and benefits.  In particular:
• The macroeconomic literature is quite inadequate;
• The microeconomic literature comes mainly from interventions implemented
individually in the context of epidemiological trials; evidence of costs and health
effects of large scale programme implementation is very limited.  Health effects
were translated into a monetary value using a somewhat arbitrary ceiling ratio.
• For the basic health services opportunity, benefits for children only are valued
although other population groups are likely to benefit.
• Evidence from successful programmes is hard to interpret, since external factors
may also have affected changes in health effects.
In addition, our estimates suffer from other shortcomings:
7• Available costs were usually costs to the provider, excluding costs to users
• Resource savings were rarely included in the estimates
• We were unable to be explicit on which groups would benefit most under each of
the challenges, and in particular on the extent to which the poorest would benefit.
Finally, macroeconomic estimates of benefits and calculations made from cost-
effectiveness evidence cannot of course be assumed to be reflecting the same
dimensions of benefits.
Given the weakness of the evidence base, it would be unwise to read too much into
detailed differences between or within opportunities.  However, a clear message from
the calculations is that in general, the benefits from investing in communicable disease
control greatly exceed the costs.  It remains unclear whether greater priority should be
given to controlling one specific disease, such as malaria or HIV/AIDS, or to a package
of priority health services, and the decision will depend to a considerable degree on total
funding available. However it cannot be emphasised enough that these three
opportunities are not completely independent – both malaria and HIV/AIDS control
must include a substantial component of strengthening health services if they are to be
successful.
Finally, it should be noted that the productivity of health expenditure is likely to be
greater both in a supportive policy environment, and where complementary investments
take place, for example in female education.
81. The challenge of communicable disease
Over the second half of the twentieth century, the world has seen enormous
improvement in health.  Between 1960 and 1995, life expectancy in low income
countries improved by 22 years, in contrast to 9 years in developed countries (1).
However, developing countries have benefited unequally from health gains (2): the
large life expectancy gap between developed and developing countries in the 1950s has
changed to a large gap between developing countries with persisting high mortality
(mainly in SSA), and those who have experienced rapidly falling mortality (Figure 1.1).
For example, average adult life expectancy is below 40 years in several countries in the
developing world, particularly in those severely affected by HIV such as Botswana.
Sierra Leone has the highest mortality rates for infants and children under 5 years old in
the world (3).
Of the 57m deaths in the world in 2002, nearly 20% were children under 5, and 98% of
these were in developing countries (4).  Communicable diseases represent 7 out of the
top 10 causes of child deaths in developing countries, and account for around 60% of all
such deaths (Table 1.1).   Just over 30% of all deaths in developing countries are of
adults aged 15-59, in contrast to 20% in developed countries, representing a substantial
problem of premature adult mortality with strong economic implications.  Within
countries, the poorer groups have substantially poorer health than the better off: for
example in Cambodia under five mortality in the poorest quintile, 147 per 1000, was
three times that of the richest quintile, and in the Central African Republic, under five
mortality of 189/1000 in the poorest quintile was double that of the richest quintile (5).
Figure 1.1: Life expectancy at birth, 1955-2002 (WHO 2003)
20
70
30
80
0
1960 1980 2000 20201940
60
50
40
10
Year
Li
fe
 e
xp
ec
ta
nc
y 
at
 b
irt
h 
(y
ea
rs
)
Developed       
Developing – low mortality
          Developing – high mortality
9Table 1.1 Leading causes of death in children in developing countries, 2002 (2)
Rank Cause Numbers (000) % of all deaths
1 Perinatal conditions 2 375 23.1
2 Lower respiratory infections 1 856 18.1
3 Diarrhoeal diseases 1 566 15.2
4 Malaria 1 098 10.7
5 Measles 551 5.4
6 Congenital anomalies 386 3.8
7 HIV/AIDS 370 3.6
8 Pertussis 301 2.9
9 Tetanus 185 1.8
10 Protein-energy malnutrition 138 1.3
Other causes 1 437 14.0
Total 10 263 100
The analysis of avoidable mortality undertaken by Working Group 5 of the Commission
on Macroeconomics and Health (CMH) highlights the importance of focusing on
communicable disease (1).  Avoidable mortality is a population’s excess risk of dying
before age 70, as calculated by comparison with the death rates in another population: in
this case non smokers in the richest countries.  Table 1.2 shows that almost 90% of
deaths in children under five are avoidable, and 84% of deaths in women aged 5-29.
Avoidable mortality due largely to communicable disease represents around 90% of all
avoidable mortality in all age/sex classes other than middle aged men, for whom it is
80%.
Table 1.2: Risk of dying and avoidable mortality (%) in low- and middle-income countries, 1998  (1)
          Males at ages        Females at ages
Risk of dying 0 to 4 5 to 29 30 to 69 0 to 4 5 to 29 30 to 69
Low- and middle-income  countries (a) 8.6 6.1 35.0 8.2 5.6 26.7
Nonsmoking, high-income population (b) 1.2 2.2 19.2 1.0 0.9 12.6
Excess risk of dying (avoidable mortality) in low- and
middle-income countries (c = a – b) 7.3 3.9 15.7 7.2 4.7 14.2
Relative contribution of avoidable mortality  to risk of
dying in low- and middle-income countries (d = c/a) 86 63 45 88 84 53
Relative contribution of Group 1* causes to avoidable
mortality 91 94 80 93 97 91
*Communicable diseases, maternal conditions, perinatal conditions, nutritional deficiencies
Historically, rapid declines in mortality have been the result of access to better housing,
sanitation and education, growing incomes, and public health measures such as
vaccination.  The benefits of research mean that tools and approaches now exist to
address the great majority of the burden of communicable disease, most notably
malaria, TB, and HIV/AIDS, as well as vaccine preventable diseases.  This helps to
explain the current international focus on tackling these diseases.  However, as Table
1.1 demonstrates, large numbers of people do not have effective access to prevention
and treatment, and as a result die.  For example, coverage of DPT31 is under 50% for
children in households living below the poverty line of $1 per day (5); and only 2% of
                                                
1 The third dose of the DPT vaccine, commonly used as a proxy for vaccination coverage
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children are protected from malaria by sleeping under insecticide treated mosquito nets
in Sub-Saharan Africa (6).
The control of communicable disease is achieved by some combination – depending on
the disease – of action through a health service infrastructure and through specific
targeted efforts which in some instances depend on the infrastructure and in others are
independent of it.  Hence the evaluation of the case for controlling specific
communicable diseases cannot ignore its relationship with the health system.  However,
issues of whether successful health improvement can be achieved by general health
system strengthening, or by targeted efforts focused on specific diseases, have been the
subject of considerable controversy (7).  The reality is that with the very unusual
exception of diseases that can be eradicated (notably smallpox in the past and polio in
the future), sustainable health improvement requires some combination of a
strengthened and accessible health service plus focused efforts to strengthen the control
of priority diseases.  Nonetheless, given limited resources, there are choices to make,
which this paper seeks to evaluate.
The paper has chosen to focus on three opportunities:
• Malaria control
• HIV/AIDS control
• Scaled up basic health services.
As emphasised above, this definition of the opportunities should not be taken to imply
that these are completely distinct efforts.  Expanded and improved basic health services
are a precondition for malaria and HIV/AIDS control, though also address a much
broader range of conditions including other communicable diseases such as acute
respiratory infections, diarrhoeal diseases, TB, vaccine preventable diseases, and
maternal/perinatal conditions.  This categorisation of opportunities has been chosen
largely because malaria and HIV/AIDS are major causes of disease burden and
economic losses; cost-effective interventions are known to exist for their control; there
is recent literature which can be drawn on to estimate costs and benefits; and these
diseases are currently the focus of world attention.  Basic health services have been
chosen as the third opportunity since they address a major part of the disease burden
affecting poor countries, and represent explicitly the infrastructure that needs to be in
place for people’s main health needs to be met.
The following section provides an overview of the economic benefits of improved
health, discusses the availability of evidence, and outlines the overall approach taken in
the paper to estimating costs and benefits.  Subsequent sections address each
opportunity.   A final section discusses methodological weaknesses and limitations, and
draws conclusions.
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2 Assessing the opportunities
2.1 The economic benefits of improved health and the availability of
evidence
Health has both consumption and investment benefits.  In other words, it is valued for
its own sake, as well as a means to achieve other goals (such as a good income).  The
relationship between illness and income is complex, as illustrated in Figure 2.1 (8).
Effects are felt both directly (through the immediate impact of ill health on productive
activities) and indirectly, via the effects of illness on fertility, morbidity,
mortality and intellectual capacity, and hence on the labour force size, composition and
quality, and on the capacity of countries to engage in the global economy.
Disease has been shown to have a major impact on the economy through these effects
on productivity, education, and investment.  As people fall ill, they are less likely to be
able to work and less likely to be productive if they can.  People have weaker incentives
to invest in their education if it is uncertain that they will be alive to reap the benefits.
There is also less incentive for people to save for their retirement, as shorter life spans
reduce the value of saving and investment in productive assets.  As foreign investors
withdraw their money from these areas, the economic costs of disease are exacerbated
(9).   However, it has been argued that effective intervention can thrust the economy just
as powerfully in a positive direction.  Better health can lead to a demographic transition
and economic growth in the long term.  Initial reductions in child mortality are followed
by a decline in fertility.  As the flood of new children mature and reach working age,
and a larger proportion of people are able to contribute to the economy, the wealth of
the society rises substantially as is argued to have happened in East Asia between 1965-
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Figure 2.1: Channels through which illness reduces income  (Ruger, et al 2001) 
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2 (9).  The massive improvements in public health that occurred in East Asia between
1965-1990 most powerfully show these effects, and  may have accounted for as much as
1.68% of its economic growth during this period (10).
The CMH recently argued that the impact of health on economic development has been
underestimated (8, 11), and that health improvements globally during the 20th century
contributed as much, or more, to improvements in economic welfare as the innovations
and expansion in material goods and services.  Such conclusions have been drawn from
studies which seek to explore the determinants of economic growth, and in particular
the influence of improved health status.  From the perspective of this paper, this
literature presents two problems: it is not disease specific; and it does not address well
what type of action might best improve health.
Empirical studies of the relationship between disease and economic outcomes fall into
two categories: microeconomic and macroeconomic.  The former study the link between
disease/ill health at household or individual level.  Usually they document the costs that
disease imposes on the household, but not explicitly the benefits of disease control.
Costs are commonly categorised as direct (household and government expenditure on
prevention and treatment), and indirect (loss of productivity due to illness and death).
There are strong reasons to believe that this simple methodology does not measure the
true economic impact of a disease, not least because in response, households and firms
adapt their productive activities, or ‘cope’.  Coping mechanisms are defined as
strategies adopted by family members, friends and colleagues to minimise the effects of
an illness on the welfare of all concerned (12).  Sauerborn et al. identified 11 different
kinds of household coping behaviours in response to illness episodes of all kinds in
rural Burkina Faso (13).  The most commonly used strategy was intra-household labour
substitution in response to lost work time of household members.  Direct costs were
usually met by mobilising cash reserves and savings, selling livestock, or receiving gifts
from other households.
Such strategies may have knock-on effects through depleted capital stock, lost savings
and indebtedness.  The sale of assets such as livestock potentially jeopardises the
household asset base, with households emerging more vulnerable and less able to cope
with further crises (13).  A household without livestock, and unable to rely on gifts, may
be forced to take out loans which could lead to serious debt and future impoverishment
(12).  These knock-on effects ultimately affect supply or production through low saving
and investment.  Furthermore, this means that the causal relationship by which disease
affects the economy may not necessarily be through sick labour only, but also through
lost capital and purchasing power.
 The potential for labour substitution crucially affects the degree to which any loss of
time is translated into a loss of output. Unemployment and underemployment are
common features of underdeveloped economies, and farming is often undertaken
communally, in households or extended families.  In the event of temporary disability of
a household member, the family workforce may provide a cushion, limiting the
consequent loss of output.  During some seasons, agricultural underemployment may be
so prevalent that time lost by sick individuals can be fully compensated for.  Similarly
in the industrial and service sectors, other members of the workforce may cover to some
extent for sick colleagues.
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 However, even if market output were maintained, there may be costs associated with
labour substitution, depending on the value of the activities from which the substituting
labour is withdrawn (12).  Moreover, assessment of a single measure of household
output, such as agricultural production, will not capture the total impact on household
welfare as it ignores the quantity and quality of home production such as food
preparation or child care, and participation in other activities, such as education or
social organisations.
 
 Coping strategies are likely to respond not only to actual illness, but also to the risk of
disease.  The risk of poor health status may have a pervasive effect on economic
incentives, behaviour and strategies (14). Households and firms respond with
anticipatory coping strategies, ranging from insurance mechanisms to changes in the
organisation of productive activities (12).  Although formal insurance is rare in
developing countries, informal mechanisms are common, including social networks and
community organisations, and incur administrative costs which produce efficiency
losses in comparison with a risk-free setting.  Precautionary measures affecting the
organisation of economic activity are likely to have wide-reaching economic effects.
High rates of absenteeism may engender labour supply responses such as limiting staff
specialisation and maintaining labour reserves to reduce the risk of labour shortages at
key times of the year, reducing the average labour productivity of all staff.  Households
may respond to the risk of high financial expenditure for serious illness by reducing
their level of investment, or investing in assets which have higher liquidity but lower
returns.  Finally, the risk of disease may affect reproductive as well as productive
strategies, for example increasing desired family size to insure against high rates of
child mortality and increase the family’s ability to cope when illness occurs (12).
The impact of these anticipatory coping strategies cannot be captured by comparing
households or firms exposed to the same degree of risk because they reduce the average
productivity of all households and firms, not just those experiencing illness during the
study period. Thus microeconomic estimates are likely to be an underestimate.
In contrast, macroeconomic studies assess the influence of a disease on national income
in cross-country comparisons, and methods and data permitting, are better able than
microeconomic studies to reflect the wide-ranging and dynamic implications of ill
health.   Again such studies usually document the cost of disease, but only by
implication the benefits of reduced disease.  Compared to microeconomic studies, the
volume of the macroeconomic literature is far more limited.   Apart from the many
econometric difficulties encountered such as omitted variable bias, there are problems in
measures and data on disease prevalence, leading to some uncertainty on whether such
studies really are picking up the impact of the disease in question.
There is some considerable overlap in the literature on the economic impact of malaria
and that of HIV in terms of the mechanisms of influence.  To a considerable extent ill
health has common effects on households and the broader economy, though these can
also differ depending on the nature of the disease.  In particular, HIV/AIDS affects
primarily adults, and malaria affects mainly children (in high burden settings), leading
to some distinctly different effects (for example, malaria in children is unlikely to lead
to the dissolution of a household, whereas HIV might well do so; severe malaria in
children can have long term effects on intellectual development).  For convenience in
reflecting the body of evidence on each of the diseases, the detailed evidence on
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economic impact is included in the disease specific sections, although this inevitably
leads to some repetition of mechanisms between sections.
Studies – of which there are many – which evaluate actual interventions almost always
have employed the analytical approach of cost-effectiveness analysis (CEA) rather than
cost-benefit analysis (CBA), thus calculating cost per unit of health effect (such as a life
saved, or a Disability Adjusted Life Year (DALY)2 averted).  Using these studies to
evaluate the efficiency of health interventions in units that are comparable across
economic sectors requires a monetary value to be placed on a human life.  This value,
the value of a statistical life (VSL), is intended to represent the marginal cost or benefit
of saving a life to society (15).  Two approaches may be taken to determine the VSL.
The Human Capital approach assumes that productivity is a proxy for utility and
estimates the VSL in terms of the present value of an individual’s future earnings.  It
can be assumed to provide a lower bound on the value of life.  Alternatively, a
Willingness-to-Pay approach may be used, which assumes that an individual’s
preferences are reflected in his actual or hypothetical choices according to market
prices.  To translate cost-per-health effect into monetary metric, either of these
approaches may be used.  While research on the willingness-to-pay for a human life has
been done in high-income countries (16), estimates for low income countries rely
largely on expert opinion.  For example the CMH argued that conventionally, each
DALY can be valued at ‘a multiple of annual income’ (17).  Lower cut-off points are
more normally applied in low and middle income country settings: for example $25 per
DALY as a criterion for a ‘highly attractive’ intervention, and $150 for an ‘attractive’
intervention (c1996 values) (18).  In contrast, it has been argued that the UK cut off is
around £30,000 (c$54,000), and possibly as high as £45,000 (c$80,000) (19), reflecting
approximately two times per capita income.
Two other issues arise in drawing on this cost-effectiveness literature, which stem from
its origin in clinical trials.  Firstly, the evidence of efficacy produced by trials may
provide a poor guide to the impact expected from routine service provision3.  Secondly,
such trials usually evaluate an intervention delivered on its own (eg insecticide treated
nets (ITNs) for malaria control) whereas in reality packages of interventions are
provided (eg ITNs plus treatment of child fevers).  Interventions may be synergistic or
competing, making it difficult to extrapolate the benefits of packages.  Finally, the
quantity of literature is very limited with respect to both geographical coverage and the
range of interventions that require evaluation.
Nonetheless, these cost-effectiveness studies represent an important source of evidence.
Moreover, systematic approaches have recently been applied to the synthesis of both
epidemiological studies and economic studies4, making judgements on the quality of the
evidence, and drawing conclusions on both the health outcomes of interventions and
cost-effectiveness.  Given the existence of these syntheses for both malaria and
HIV/AIDS interventions, this paper relies on these reviews rather than the original
studies.
                                                
2 DALYs are probably now the most commonly used unit of health outcome.  They sum years of life
gained and years lived with disability, weighted by the severity of the disability.
3 Epidemiologists distinguish efficacy, that obtained under ideal conditions (usually a research study),
with effectiveness, that obtained under more normal service conditions.
4 The Cochrane library is one of the most up-to-date catalogue of reviews on the appropriateness and
effectiveness of medical interventions, and can be accessed at
http://www.cochrane.org/reviews/clibintro.htm
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Benefits of disease control include not only health benefits, but also resource savings, as
when preventive interventions reduce the need for treatment.  While some cost-
effectiveness studies take these into account, in general they are often neglected, in part
because of equity concerns: resources are only saved if used in the first place, and those
population groups which have worst access to care will spend less (and have less spent
on them).
2.2 Methodological approach adopted
Given the limitations of the literature, the following approach was adopted.  In general,
conservative assumptions were made.  For each opportunity, several different
approaches were adopted to estimate costs and benefits.  For the two diseases (malaria
and HIV), evidence was drawn from three different sources:
• Studies of the macroeconomic impact of the disease
• Studies of the cost-effectiveness of interventions
• Evidence of the costs and health benefits of large scale programmes.
For basic health services, evidence was drawn from three different sources:
• Regression analyses that measured the effectiveness of health expenditure in
generating health outcomes
• A major report to determine the cost of interventions that should take priority
• An analysis that determined the costs and benefits of a package of interventions that
was recommended in the 1993 World Development Report.
Given the limitations of the literature in terms both of quantity and quality, and the need
to try and be comprehensive in estimates of costs and benefits, these were where
possible calculated by the authors based on the literature rather than limiting the paper
only to costs and benefits actually provided in the literature.  This also enables the paper
to seek some degree of consistency in terms of years and scope of costs and benefits.
Since the literature has very limited and patchy geographical coverage, rather than make
heroic assumptions extrapolating country specific analyses to the whole developing
world, costs and benefits were calculated for the geographical entity from where the
evidence came.  While this means that estimates cover very different areas, taken
together the evidence gives a sense of the overall balance of costs and benefits.
Given the geographical focus of this paper, benefits accrue to the populations of low
and middle income countries and if valued according to exchange rate conversions,
would understate benefits when compared to another challenge where benefits to high
income populations are included.  Costs and benefits were therefore adjusted for
Purchasing Power Parity (PPP), and expressed in 2003 international dollars (Int$).  Each
year of life lost (YLL), or DALY5, was valued at per capita Gross National Income
(GNI). Depending on the population served, the corresponding GNI was used to
represent this value, or ceiling ratio (Table 2.1).  While this choice of value is arbitrary,
it is a conservative reflection of the level of its income the developed world is willing to
spend on saving a year of life.  To avoid disadvantaging low income countries (since the
lower their income, the lower the value of benefits), results were recalculated in the
                                                
5 both were used, depending on the original source.  In general, for the conditions considered here which
cause death, YLLs dominate in the DALY and so the values are very similar
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sensitivity analysis using a standard value of Int$3,830/YLL or DALY averted, the
mean GNI for low and middle income countries.
Table 2.1: Value of a DALY/YLL
Region 2001 PPP adjusted per-capita
GNI (2003 Int$)
2001 per-capita GNI (2003
US$)
Low & middle income $3,830 $1,160
East Asia & Pacific $3,790 $900
Europe & Central Asia $6,320 $1,970
Latin America & Caribbean $6,900 $3,580
Middle East & North Africa $5,430 $2,220
South Asia $2,570 $450
Sub-Saharan Africa $1,750 $460
Thailand $6,230 $1,940
South Africa $10,910 $2,820
Figures taken from (3).
Costs were calculated from a social perspective (ie including costs to both providers and
users) where data permitted, though they often reflected provider costs only. Reductions
in treatment expenditures arising from disease prevention were included where possible.
To make results comparable to those in other Challenge Papers, estimates were
presented in terms of annualised net-benefit (ANB) and benefit-cost ratios (BCR).
Where absolute levels of benefits and costs could not be estimated from information
given in the literature, benefits were estimated from cost effectiveness ratios by dividing
them by the ceiling ratio appropriate to the study.  Where it was possible to estimate
total costs and benefits, net-benefit was calculated with the equation (1):
CostsBenefisRNB CIndividual −∗= )( (eq. 1)
where Rc represents the ceiling ratio.  Evidence of absolute costs and health benefits
was given in two estimates from successful programmes (20) (21).  Costs and benefits
for individuals were calculated for other estimates, and scaled up to incremental target
coverage levels for the population in need (PIN) (equation 2).
PINCoverageNBNB IndividualTotal ∗∗=    (eq. 2)
Where possible, costs and benefits were estimated for the period 2002 to 2015 (to
coincide with the Millennium Development Goals (MDGs)) and MDG targets were
used, where relevant, to establish the desirable scale of interventions.  Costs and
benefits were adjusted by a discount rate (DCR) of 3%.  Sensitivity analysis was used to
explore the sensitivity of costs and benefits to changed assumptions, including a higher
DCR (6%) and common ceiling ratio (Int$3,830).
For all models, it was assumed that scaled up coverage targets were achieved
instantaneously.  Where specific evidence was unavailable, parameter values were
extrapolated assuming linear growth rates and relationships between data points
calculated as incremental values: additional amounts relative to the costs and benefits of
existing programmes.
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3 Control of malaria
3.1 Identification and description
Introductory statistics
Malaria is the most important of the parasitic diseases of humans.  Transmission occurs
in 103 countries; more than 1bn people live in malarious areas; and between 1-3m
people die from malaria each year.  Malaria was eradicated from North America,
Europe and Russia over the twentieth century, and for a period was substantially
controlled in much of South Asia, but in recent decades has resurged.  The increased
threat from malaria is particularly a result of international neglect of the disease in the
1980s onwards following realisation that malaria eradication was not feasible; and
major and increasing problems of resistance to the most commonly used drugs and
insecticides.
Malaria is caused by four different species of the genus Plasmodium, of which the most
dangerous is P. falciparum.  Human infection occurs when the malaria vector, a female
mosquito of the Anopheles genus, inoculates sporozoites from its salivary glands when
it bites humans.  The parasite reproduces within the human host, and the disease is
transmitted by gametocytes in the blood meal when further female anophelene
mosquitoes feed on the infected individual.
Epidemiological description
Malaria is primarily a tropical disease.  P. falciparum predominates in SSA, which as a
result bears over 85% of the disease burden and 90% of malarial  deaths.  P. vivax is
more common in Central America and the Indian subcontinent.  The epidemiology of
malaria is complex, varying considerably from place to place.  Transmission is termed
stable when infection occurs all year round.  In these settings small children are infected
repeatedly early in life, and morbidity and mortality are considerable: (22, 23).  Through
repeated infection children develop immunity, meaning that as adults they may suffer
febrile episodes but are very unlikely to die from malaria.  Pregnant women are the
other population group at high risk, since their immunity is impaired especially in the
first pregnancy.  In contrast, where transmission is low, unstable or very focal (termed
unstable transmission), immunity is not acquired and symptomatic disease may occur at
all ages. Areas with unstable malaria are prone to epidemics – for example northern
India, Sri Lanka, Southeast Asia, southern Africa – which can cause many deaths.
The number of children dying of malaria rose substantially in eastern and southern
Africa during the first half of the 1990s as compared to the 1980s, while in West Africa
there was little change in the overall malaria mortality rate in children (6).  The most
likely explanation is the rapidly increasing levels of resistance to chloroquine (the most
widely used treatment drug) in eastern and southern Africa.
 Defining and measuring the malaria disease burden
 
 Defining and measuring the health burden of malaria presents some major difficulties.
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 Mortality
 Estimating the number of deaths due to malaria is notoriously problematic (24).  Post-
mortem questionnaires are relatively insensitive for detecting malaria deaths, because of
the similarities between the symptoms of malaria and other severe diseases, such as
pneumonia (25).  Official reporting systems are often unreliable, as in many areas of
Africa the majority of deaths occur at home and are not formally registered.
 
 Malaria can contribute to death in young children in three main ways:
 
• an overwhelming acute infection can kill a child quickly
• repeated infections contribute to the development of severe anaemia, which
substantially increases the risk of death
• low birthweight, a frequent consequence of malaria infection in pregnancy, is the
major risk factor for death in the first month of life.
In addition, repeated infections make young children more susceptible to other common
childhood diseases.
In SSA it is estimated that around 20% of mortality of children under 5 is due to
malaria, and malaria is the most important single infectious agent causing death in
young children.  Around 1m deaths (range .744-1.3m) are estimated to occur in Africa,
more than 75% of them in children (26).
 
 Episodes of uncomplicated malaria
 Uncomplicated malaria is typically treated on the basis of clinical symptoms alone.
400-900m acute febrile episodes are thought to occur yearly in African children under 5
living in endemic areas (26).  If 30-60% of these children were parasitaemic, as reported
in some studies, malaria cases in children would be 200-450m annually.  Older age
groups in Africa have around 0.4-1 episodes of malaria a year, and probably 2 or more
febrile episodes.  Worldwide there may be well over 2bn febrile episodes annually
resembling malaria.
 
 Severe disease
 Severe malaria has two major clinical syndromes: malaria with respiratory distress; and
malaria with neurological disturbance, or cerebral malaria (27). These occur primarily
among children, but also affect adults in areas of low or unstable transmission.  An
estimated 3% of all attacks are severe, and in the absence of inpatient treatment around
half of cases are likely to die (28).  Even with optimal management of treatment, case
fatality rates for cerebral malaria are around 19%, and would be much higher in many
hospital settings in Africa given lack of resources and skilled staff.
 
 Anaemia
 Malaria is an important cause of anaemia in SSA (24).  The severe form is a life-
threatening condition in young children and often warrants blood transfusion, which
increases the risk of HIV infection.  In malaria-endemic areas, the incidence and age
pattern of severe anaemia are strongly dependent on the intensity of P. falciparum
transmission (29), and malaria control trials have been associated with significant
reductions in the prevalence of anaemia in children and pregnant women (30).
 Malaria in pregnancy
 Anaemia is also a harmful manifestation of malaria in pregnancy. Pregnant women, as a
result of malaria infection and especially in their first pregnancy, experience an
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increased risk of maternal anaemia, abortion, still birth, and low birth weight, due to
both prematurity and intra-uterine growth retardation (31).  This is of particular concern
because low birth weight is associated with increased neonatal mortality (32).
 Interaction with other diseases
 In addition to its direct role in morbidity and mortality, malaria is also thought to have a
significant indirect effect in conjunction with other common diseases such as measles,
respiratory infections, diarrhoeal disease and malnutrition, although the extent of the
indirect impact is difficult to measure and not well understood.  Evidence for a
significant indirect effect is bolstered by malaria control trials which have found much
larger reductions in all-cause mortality than would have been expected from data on
malaria specific mortality alone (30).  Moreover, the use of insecticide treated mosquito
nets (ITNs) has led to reductions in deaths attributed to acute respiratory infections,
acute gastro-enteritis and malnutrition as well as malaria (33).  However, during the
Garki project of residual spraying and mass drug administration, malaria control led to
less than the expected impact on all-cause child mortality, which may be because
children face “competing risks” from other potentially fatal diseases, so that a reduction
in malaria risk increases their likelihood of falling victim to another cause (34).
 
 Intellectual development
 Although evidence is limited, it is likely that malaria significantly affects intellectual
development and since variations in reasoning ability, cognitive skill, and years of
schooling are considered to be important determinants of future variations in
productivity and earnings of individuals (35), the economic impact is likely to be
significant.
 
 Survivors of cerebral malaria may be left with neurological sequelae including
weakness in the limbs, speech disorders, behavioural disorders, blindness, hearing
impairment, cerebral palsy and epilepsy.  A review of comparable studies of African
children found that 16% of cerebral malaria survivors had some kind of neurological
sequelae at discharge, and for 6% of children these defects persisted for at least 6
months (24).  No data were available on residual sequelae among adults.
 
 There is good evidence on the association between iron deficiency anaemia (IDA) and
poor performance in infant development scales, IQ and learning tasks in pre-school
children and educational achievement among school-age children (36). Iron
supplementation has been associated with improvement in mental development scale
scores in infants (37) and significant increases in school achievement scores (38).
However, it is not clear whether these findings for IDA apply equally to children with
the type of anaemia associated with malaria.
 
 Malaria may also affect intellectual development through the impact on school
attendance.  A study in the Gambia of the effects of insecticide-treated mosquito nets
found that absenteeism because of fever was significantly higher in the control group
(39).
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Microeconomic Impact of Malaria
Microeconomic studies are concerned with impact at the level of a productive unit such
as the household or firm.  There is quite a voluminous literature, which we lack space to
cover here but which is reviewed in (40).
 Evidence on direct costs suggests that households can spend quite substantial sums on
prevention and especially treatment, and also that direct costs to governments are
substantial (for example an estimated 19% of the Rwandan Ministry of Health recurrent
budget (41). In terms of indirect costs, the average time lost per episode for a sick adult
ranges from 1 to 5 days, though these averages conceal considerable variation across
individuals (40).  In order to estimate total costs, Ettling et al. (42), using data from
Malawi, multiplied the cost per episode by the predicted number of episodes per year
and average household size to obtain a total annual cost per household of $40.02 or
7.2% of household income.  For very low income households the total cost was $24.89,
equivalent to 32% of income.  Leighton and Foster (43) found that total household costs
amounted to 9-18% of annual income for small farmers in Kenya, and 7-13% in
Nigeria. Only one study, by Shepard et al. (44), has attempted to use such data to
estimate the overall economic cost of malaria morbidity and mortality in Africa. Based
on extrapolations from four country case studies in Burkina Faso (one district), Chad
(one district), Congo (Brazzaville), and Rwanda, the total direct and indirect cost in
1987 was estimated to be $1,064m, $3.15 per capita, and 0.6% of the sub-Saharan
Africa GDP (1999 prices). The authors predicted that the total cost would increase
substantially over time based on projected increases in population, malaria incidence,
the value of output, and the cost of antimalarials.
 
However this evidence on the microeconomic impact of malaria is in general partial and
of questionable accuracy (40, 45), and there are many problems in using such data to
reflect the burden to society or the potential benefits from control. Studies have
generally focussed on febrile illness, overestimating the burden of uncomplicated
malaria but underestimating the costs of severe illness, other debilitating manifestations
(especially neurological sequelae, anaemia and cognitive development), and mortality.
Many studies use inadequate data to calculate indirect costs, failing to account for
seasonal variations, the difference between the average and marginal product of labour,
and the ways households and firms “cope” in response to illness episodes.  An
alternative approach has been to estimate the net impact on output by looking directly at
the statistical association between malaria and agricultural output through a production
function (46). Findings have been contradictory, at least in part because of data and
methodological weaknesses.
The evidence on the extent to which the burden falls more heavily on lower socio-
economic groups is reasonably consistent (47).  Studies examining socio-economic
status using assets, education, and occupation all yield data that suggest an inverse
relationship between the impact of malaria and socio-economic status.
Evidence on the impact of coping strategies in response to the risk of disease is
fragmentary.  Such strategies probably affect fertility decisions and crop choices, for
example, but are difficult to identify since they reduce the average productivity of all
households and firms, not just those experiencing illness during the study period. It is
ironic that precautionary measures against the risk of malaria may lead analysts to
conclude that the economic impact of malaria episodes is low, when the reverse is the
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case.  For example, maintaining a labour surplus, which is very costly to firms or
households, would permit a high degree of labour substitution in response to a single
episode.
 Macroeconomic impact of malaria
 
 Studies of the macroeconomic impact of malaria have produced conflicting results.
Barlow (48) analysed the impact of near-eradication of malaria in Sri Lanka using a
macro model which encompassed both demographic and economic variables, such as
the labour force, savings and investment and public expenditure.  He argued that,
although there may have been a positive impact during the first decade, in the long-run
the growth of output would have been outstripped by population growth, reducing real
income per capita.  These conclusions should be treated with caution for several
reasons.  The impact of malaria eradication on population growth in Sri Lanka has been
a subject of great controversy, with some analysts arguing that its contribution was
much lower than that assumed by Barlow.  Borts argued that malaria control may
change household savings behaviour if the productivity of capital is increased through,
for example, the opening up of more productive land (49).  More generally, models such
as Barlow’s have been criticised for over-emphasising the role of capital formation in
economic growth.  Finally, the relevance of Sri Lanka’s experience to contemporary
Africa is questionable, given that population density and demographic trends are very
different, and malaria interventions focus on control rather than eradication.
 
 A recently applied alternative approach has been to use malaria as an explanatory
variable in economic growth models in the style of Barro (50).  Gallup and Sachs (2001)
used cross country regression analysis to relate the growth in GDP per capita between
1965 and 1990 to initial income levels, initial human capital stock, policy variables,
geographical variables and a ‘malaria index’, calculated as the product of the fraction of
land area with endemic malaria in 1965 and the fraction of malaria cases that were P.
falciparum in 1990 (51).  Their results suggested that countries with a substantial
amount of malaria grew 1.3% per year less between 1965 and 1990 (controlling for
other influences on growth), and that a 10% reduction in malaria was associated with
0.3% higher growth per year.  McCarthy et al. employed a similar cross-sectional
regression approach to explore the impact of malaria on average per capita growth rate
in three five-year periods.  They proxied the malaria burden with data on the incidence
of malaria episodes, to account for the impact of differing use of protective measures on
actual morbidity with given exposure (52).  They also found a significant negative
association between malaria and economic growth, although the estimated impact
differed sharply across countries. The impact was smaller than that found by Gallup and
Sachs, exceeding 0.25% per year in a quarter of the sample countries, and averaging
0.55% for those located in SSA6.
                                                
6 Reasons for the differences between the two models remain to be fully explored.  A potential
explanation lies in the time frame used in each evaluation; Gallup and Sachs (2001) use a dataset that
spans 1965-1990 based on historical maps, while McCarthy and colleagues (2000) use WHO data
between 1983-1997.  A sizeable proportion of the advances in malaria control were lost during the 1980s,
so the model by McCarthy et al. does not reflect many of the advances made previous to those years.
Also, Gallup and Sachs use a malaria index, which ties the burden strongly to prevalence and geography.
McCarthy et al consider that the distribution and amount of national income, along with access to health
facilities, reduces the detrimental effects to the economy.   The measure that McCarthy et al. use ties
malaria prevalence less strongly to the detrimental effects of the disease.
22
 These differences in growth rates translate into substantial differences in levels of
income: for example countries with intensive malaria had income levels in 1995 only
33% that of countries without malaria, whether or not the countries were in Africa (51).
 
 The contrasts between these results and those based on direct and indirect costs and
production functions highlights the need to develop a much deeper understanding of the
mechanisms by which malaria affects households and economies.  Without this, it is
difficult to evaluate existing estimates, both micro and macro.
3.2 Alleviation of the challenge – interventions against malaria
Compared to some tropical diseases, the epidemiological and cost-effectiveness
literature on malaria is relatively strong for some key interventions (28), though
evidence of effectiveness is almost only available for individual interventions.  In order
to approximate a more realistic scenario, we identified a limited package of
interventions whose total costs and benefits could be estimated7. Interventions were
included that minimised overlap of target groups while maximising population
coverage. Synergies in the costs and effects of different interventions was not
considered due to lack of evidence.  SSA was chosen as the geographical context, as
90% of the global burden of malaria falls on this region.
The package evaluated included two preventive interventions targeted to different
population groups and one treatment intervention.  An insecticide treated mosquito net
(ITN) programme was included to reduce infections in children under 5 years in SSA as
trials have shown they reduce overall child mortality by 19%8 (53).  However, only a
small proportion of African children under 5 years old actually receive this protection
(6).  Residual spraying of homes with insecticide and chemoprophylaxis of children
were excluded from the package as they target the same individuals.
Intermittent treatment of pregnant women (IPTp) in their first pregnancy
(primigravidae) was included to protect children from dying from complications
associated with low birth weight (54).  In 1986, the WHO advocated that all pregnant
women living in endemic areas be protected against malaria.  Since concerns exist about
the safety of prescribing new artemisinin-based combination therapies to pregnant
women (55), and chloroquine (CQ) is associated with problems of resistance and
compliance (56, 57), sulfadoxine pyramethamine (SP) is the recommended prophylactic
therapy. IPTp consists of two curative doses given during the first and second trimesters
of pregnancy during antenatal care visits.  Antenatal care is common (around 65%
coverage) in SSA; however, a  considerable amount of scaling up of IPTp is needed as
few of these women currently receive antimalarials.
A switch to artimisinin-based combination therapy (ACT) in SSA plus dipstick
diagnosis was included as the treatment intervention as existing therapies, such as CQ
and SP, are declining in efficacy. The WHO has argued that appropriate and timely case
management should be seen as a key component of any malaria control programme
(58). In reality, case management is often inadequate.  The African Malaria Report 2003
reported that more than 80% of children treated for malaria received CQ, (6).  A few
                                                                                                                                              
7 This package should not be interpreted as a policy recommendation, but is selected purely for use here.
8 Other age groups are likely to benefit from these nets, but to an unknown extent.
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countries have switched to SP, but resistance is expected to increase rapidly to this drug:
for example in Burundi, resistance to SP is already 50% (59).
Artemisinin derivatives provide an efficacious alternative to SP, and using them in
combination with longer-acting drugs is likely to slow the growth of resistance (56).
Artemisinins are eliminated from the body relatively quickly, reducing the time that
they exist at sub-therapeutic concentrations which is when mutant parasites with small
selective advantages proliferate relative to the rest of the parasite population, and drug
resistance begins to develop. These parasites can be residual parasites not yet cleared
from the initial infection, or those inoculated by a new infectious bite.  In theory, the
longer acting drug in the combination will protect the artemisinin derivative by
maintaining therapeutic levels as the artemisinin is eliminated (60).  South Africa has
fully switched its first line drug policy to ACTs, and Tanzania, Zanzibar, and Burundi
are all in the process of making the change (6).  Although the technology has still to be
fully developed for use in SSA, dipstick diagnosis was included with ACTs, in order to
target treatment to those with malaria and avoid using expensive drugs for all fevers.
In addition to changing first line therapy, scaling up programmes to expand malaria
treatment coverage is needed urgently.  Approximately 42% of children with malaria
receive antimalarials (6), and the majority of deaths in hospital occur within 24 hours of
treatment, indicating that treatment was received too late (61).  Prime reasons for low
coverage include poor physical accessibility of health facilities and low levels of
affordability of treatment (62).
3.3 Side effects
Positive side effects
Positive side effects in terms of economic development and improved individual
welfare are taken into account as far as possible in the calculations below, so are not
further discussed here.
Negative side effects
Medical interventions have both benefits and risks.  In general, the licensing process for
drugs, vaccines and chemicals used to improve human health requires good evidence on
adverse effects.  Beyond this, WHO, as the global normative authority, may choose not
to recommend that countries use a particular product if it judges the evidence of benefit
or adverse effects to be not sufficiently strong, and the balance of risks and benefits not
sufficiently positive.  That said, trials of new products can never be done in all relevant
settings, and some adverse effects are rare given the sample size of studies, but
nonetheless may be sufficiently serious to warrant withdrawal of a product.  Monitoring
systems exist in the more developed world to check for adverse reactions, though are
rarely 100% effective given the difficulties of associating adverse effects with the
product.  For products used exclusively in the developing world, it is unlikely that
adverse effects will be quickly detected unless they are very obvious.
With respect to the malaria interventions considered here, side effects are not of major
concern.  Insecticides recommended for use on nets are evaluated by WHOPES9.  SP
has been chosen as the WHO recommended drug for use in IPTp; adverse effects do
                                                
9 http://www.who.int/ctd/whopes/
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occur with SP, but are very rare. Artemisinin and ACTs have been used very widely in
China and South East Asia, and appear to have few adverse effects (63).  One specific
concern is that given limited government controls on the use of drugs in low and middle
income countries, it is very difficult to regulate the use of new drugs once available on
the local market.  This has implications for the development of resistance.  Drugs taken
in doses inadequate to cure the infection, or drugs taken by an uninfected person who
subsequently becomes infected, can expose the malaria parasite to suboptimal drug
levels, increasing the risk of resistance developing or being transmitted.  Approaches to
tackling this problem include international agreements with the pharmaceutical industry
on marketing drugs; information campaigns to educate consumers on taking full courses
of drugs; and drug retailer training programmes.  However, since it is unlikely that such
efforts will be fully effective, continued investment in the discovery of new drugs is
also needed.  This comes at a cost, which currently falls mainly on public and charitable
funds (channelled though public private partnerships such as MMV10), given  the
limited incentives for the industry to invest in drugs whose market is severely limited by
low purchasing power.
3.4 Economic evaluation
Despite the relatively large economic literature on the impact of malaria, especially at
the microeconomic level, the volume of research has not produced many estimates of
cost-benefit ratios.  Recent economic analysis has focused almost exclusively on cost-
effectiveness analysis (drawn on below) and cost benefit analyses date from the 1960s
and 1970s.  Table 3.1 below summarises their results based on a review quoted in
Najera et al (64).  These data are largely of historical interest, and are not used further
here: no estimates relate to high transmission settings in SSA, and all rely on control
methods (largely residual spraying) which are not favoured today in high transmission
settings.  However, the attractive benefit cost ratios should be noted.
Table 3.1: Cost-Benefit Ratios in Malaria Control
Source Country Method Benefit Cost Ratio
Barlow 1968 Sri Lanka Insecticide 146
Griffit, Rampana, and Mashaal 1971 Thailand Chemoprophylaxis 6.5
Khan 1966 Pakistan Eradication program 4.9
Livandas and Athanassatos 1963 Greece Eradication program 17.3
Niazi 1969 Iraq Eradication program 6.0
Ortiz 1968 Paraguay Insecticides 3.6
San Pedro 1967 Philippines Eradication program 2.4
Democratic Republic of Sudan 1975 Sudan Control program 4.6
Source: Barlow and Grobar 1986.
BCRs and ANBs were estimated for SSA, drawing on recent evidence. Three
approaches were taken:
1. macroeconomic evidence was used to estimate the economic costs associated with
the burden of malaria and the benefits of malaria control, and related to recently
estimated costs of control
2. the intervention package was evaluated based on microeconomic estimates of cost-
effectiveness.
3. calculations of costs and benefits were made for Kwa-Zulu Natal in South Africa,
which recently changed to an ACT.
                                                
10 Medicines for Malaria Venture
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Macroeconomic Approach
The Gallup and Sachs (51) and McCarthy et al. (52) models reviewed above predicted
the additional amount that economies would have grown if malaria had been eradicated,
the first predicting an additional 1.3% per person growth in annual GDP, and the second
an additional 0.55%.  While it is unreasonable to expect that current measures against
malaria will be able to eradicate the global burden, the United Nations Millennium
Project has set a goal to halve the malaria burden in sub-Saharan Africa by 2015 (65).
Assuming that incremental reductions in malaria elicit economic payoffs at a constant
rate, we extrapolated the economic benefits that would result if the Millennium
Development Goal were reached.  This extrapolation was determined according to a
linear function between current and predicted malaria levels.
Working Group 5 (WG5) of the CMH estimated the annual per-capita cost of a package
of interventions that would be necessary to achieve the MDG (1). For adults, it included
recurrent and annual equivalent capital costs of measures to prevent and treat malaria.
The costs of treating childhood malaria were aggregated with other medical costs for
childhood illness in this report, and we used these costs in their entirety.  Costs were
averaged across high and low estimates, and discounted into the future.  Overall, the
cost of reaching the MDG would be Int$21 per person per year.
We calculated benefits by taking the difference between baseline and intervention
scenarios of per-person GDP growth.  A baseline scenario of economic growth with
current levels of malaria was established based on the average annual GDP growth rate
in SSA between 1990 and 2001 (2.15% per person per year) (66).  From this baseline,
we extrapolated the benefit of reducing the malaria burden by 50% for the 563 million
people living at risk.  Results are shown in table 3.2.
Table 3.2: Costs and benefits of malaria control estimated from macroeconomic models (2003 Int$)
Study used Population
benefiting
Total
benefit
(millions,
2002-15)
Total cost
(millions,
2002-2015)
Net-benefit
(millions,
2002-2015)
Annualised
net-benefit
(millions)
Benefit-
cost
ratio
Gallup and
Sachs (2001)
563,282,922 $664,309 $142,473 $521,835 $43,486 4.7
McCarthy et
al. (2000)
563,282,922 $275,948 $142,473 $133,475 $11,123 1.9
Population and GDP data taken from (3)
Assumptions used for cost and benefit calculations were varied in a rough sensitivity
analysis.  With a DCR of 6%, the ANB of the Gallup and Sachs (51) model decreased
by 25%, and the ANB of the model by McCarthy and colleagues (52) decreased by
30%.
In their analysis, Gallup and Sachs (51) estimated further that a 10% reduction in
malaria would allow economies to grow an additional 0.3% per person each year.
Using this estimate as the lower limit of the function from which we extrapolated
benefits, calculations showed that a 50% reduction in malaria would result in a 0.74%
annual increase in per-capita GDP.  Total net-benefit increased from $522 billion to
$624 billion, and the BCR increased from 4.7 to 5.4.
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If costs are decreased by 25% to allow for the costs of non-malaria interventions
included in the full child treatment package, the total net-benefit in each scenario
increases by $36 billion.  The benefit cost ratio increases from 4.7 to 6.2 using Gallup
and Sachs estimates, and from 1.9 to 2.6 using McCarthy et al..  If costs are increased
by an arbitrary 25%, the BCR decreases to 3.7 for Gallup and Sachs and to 1.5 for
McCarthy et al.
Microeconomic Approach
Microeconomic evidence on the three interventions applied to SSA (ITNs for children
under 5 years, IPTp for first pregnancies, and ACTs to treat malaria) was taken from
models constructed by teams at the LSHTM which used methods of probabilistic
sensitivity analysis, thus allowing ranges of values to be used rather than single point
estimates (28, 67).  In these models, key determinants of cost-effectiveness were also
included such as drug resistance, intensity of transmission season, behavioural factors,
price of key commodities, and expected mortality.  Costs were considered from a
provider’s perspective for all interventions except for ITNs, where the cost of
community time was included.  Benefits were measured in terms of DALYs calculated
according to Mark II methods with no age weighting (68), except for IPTp which
estimated YLLs.  A standard West African life table was used for life expectancy (69).
The net-benefits of ITNs and IPTp were calculated according to income strata as used in
the original models.  Income strata were defined as having per-capita GNIs of less than
Int$1300 for very low income countries, less than Int$3,000 for middle income
countries, and above Int$3,000 for higher income countries.  Variations in income strata
affected staff salary and training costs in these models.
ITNs
The model drew evidence of effectiveness from a Cochrane meta-analysis of large scale
trials (53). Deltamethrin rather than permethrin was assumed to be the insecticide since
deltamethrin’s unit cost is lower and it lasts twice as long.  Costs in the model were
drawn from the economic evaluations that accompanied the trials, published and
unpublished literature, and expert consultation.   Trials have not been conducted in areas
of low-transmission intensity in sub-Saharan Africa, so results are relevant for areas of
high and moderate transmission.  The model measured effectiveness for children aged
1-59 months only.
Without any intervention, children aged 1-59 months in high transmission areas
experience 1 to 2.9 clinical episodes of malaria (70).   Although the ITN trials found a
19% reduction in all-cause mortality in children aged 1-59 months (53), effectiveness in
practice can be expected to be lower than effectiveness in a trial.  Households may not
re-treat their nets, children may not sleep under them during periods of hot weather,
other family members may use the nets, and nets may be taken away, destroyed or sold.
The average compliance reported in the trials was 65%.  Other studies have found that
between 20% and 80% of nets are retreated (71) and that 57% to 97% of children use
nets appropriately (33, 72, 73).  The latter two estimates were averaged to estimate
actual compliance.  A linear relationship between compliance and effectiveness was
assumed, such that zero compliance resulted in no effectiveness and 65% compliance
resulted in the reduction in mortality found in the meta-analysis.  Effectiveness results
from the meta-analysis were multiplied by the ratio of actual compliance to trial
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compliance to estimate effectiveness in a programme situation.  Based on these
assumptions, it can be expected that protected children will lose 0.19 fewer years due to
malaria than unprotected children.
Costs included insecticide, staff, transport, other overheads, community time, a
sensitisation and awareness campaign, and the cost of mosquito nets, and were updated
to 2003 values from Goodman et al. (28).  Although the programme was targeted at
children aged 1-59 months, it was assumed that 2 - 3.9 nets would need to be supplied
per household.  The overall cost of the programme was Int$28.47, Int$29.02, and
Int$33.50 per child with increasing income strata, with the cost of the net being the most
important input.
We predicted the incremental economic returns of scaling up ITN coverage in SSA
from 2% to 70% to protect an additional 61,143,375 children under five years old living
in endemic areas.  The ANB was Int$17 billion, with a BCR of 10.  Table 3.3 shows the
results by income strata.
Table 3.3: Costs and benefits of ITNs (2003 Int$)
Income strata
(value of a
DALY)
Additional
children
covered
Total benefit
(millions,
per year)
Total cost
(millions,
per year)
Annual net-
benefit
(millions)
BCR
Low income
(Int$850)
41,445,555 $6,693 $1,179 $5,513 5.7
Middle income
(Int$1,863)
14,995,918 $5,308 $435 $4,873 12.2
High income
(Int$7,250)
4,701,375 $6,477 $158 $6,319 41.1
Calculated from (3), (28), (1)
The discount rate affects only the useful lifespan of the net, and has very little effect on
ANB.  Increasing the discount rate from 3% to 6% lowers ANB by less than 1%.
Standardising the ceiling ratio to Int$3,830/DALY strongly affected the results, giving a
ANB of Int$43 billion and a BCR of 25.1.
For several reasons, the calculation of ANB given by this model may be an
overestimate. Families may wash nets more frequently, reducing effectiveness. Overall
child mortality may be lower than the predicted baseline in higher income countries, and
thus benefits may be exaggerated.
On the other hand, the calculation of ANB may be an underestimate:
• The model considers benefits only for children yet accounts for the cost of enough
nets to protect entire families. If distribution were targeted so that only one net could
be provided per child, the costs of the programme would be substantially reduced.
• The cost of nets was determined according to the price given for publicly
administered programmes; privately-managed social marketing programmes may be
able to provide nets at lower cost (74)
• A high community level of net use may protect families without nets living in the
same area, through the ‘mass effect’ (75).
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• Control households in epidemiological studies tend to have better outcomes than
unobserved families due to the Hawthorne effect11, thus producing a lower estimate
of the difference between intervention and control.
The mechanism used to deliver an ITN programme is of vital importance to its cost-
effectiveness. If the cost structure of net provision is shifted from the government to the
consumer, overall costs to government would be lower than those found in the trials
used in this analysis. However, evidence from the Gambia shows that effectiveness is
likely to decrease substantially if this shift occurs, as demand for ITNs is price elastic
(62).  Given that willingness-to-pay (WTP) for nets appears to be greater than WTP for
insecticide treatment (62), the imminent introduction of long lasting nets which do not
require retreatment may increase the effectiveness of private purchases.
Prevention in pregnancy
We based our estimates on the model of Goodman et al that evaluated the cost-
effectiveness of using SP to protect foetuses born to primigravidae (76).  This study
used evidence from a Cochrane review of strategies for preventing malaria during
pregnancy, whose outcome measure was impact on low birth weight (54).  In order to
estimate impact in terms of deaths, Goodman et al modelled the impact of low birth
weight on child survival using a Wilcox-Russell mortality curve and distributions of
birth weight for both protected and unprotected foetuses.
Under ideal conditions, this model predicts that 0.011 fewer babies born to
primigravidae will die with IPTp.  However, treatment failure can occur for several
reasons.  Women may not begin prophylaxis early enough in their pregnancy, they may
not fully comply with the drug regimen, and parasites may carry mutations that confer
drug resistance.  The model assumed that treatment was only successful if women made
at least two visits per pregnancy before the end of their second trimester, took the
correct doses at the appropriate times, and were not infected with resistant parasites.
The effective reduction in neonatal mortality rate, D, was calculated as
21*)]1[()1()1( vvzggrsdD ∗−+∗−∗−∗=         (eq. 3)
where d is the maximum level of possible effectiveness, s is the still birth rate, r is
parasite resistance, g is compliance to the correct drug regimen, z is the proportion of
under-dosed cases where treatment was still effective, v1 is the probability of attending
the antenatal clinic during the first or second trimester, and v2 is the probability of
returning for a second visit.
It can be expected that drug resistance, r, will change through time.  Based on methods
used by Coleman et al. (67), we assumed that parasite resistance grows according to a
sigmoidal trajectory using a logistic function.  Longitudinal drug resistance studies in
Eastern and Southern Africa suggest that the maximum rate at which resistance grows
to SP, ki, is between 30% and 50% per year (77).  Current levels of resistance, Ri,0, were
assumed to be 13% according to the mean of 39 sentinel sites in East Africa (59).  The
dynamic spread of drug resistance at time t was modelled using equation x.
                                                
11 http://pespmc1.vub.ac.be/ASC/HAWTHO_EFFEC.html, and http://www.accel-
team.com/motivation/hawthorne_02.html
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A 13 year time frame was used to be consistent with other calculations in this paper.
The model predicted that an average of 0.062 YLLs would be averted each year per
child born to primigravidae.
Costs were determined according to income strata and updated from Goodman et al.
(76).  It was assumed that antenatal services already existed for women receiving this
treatment, and that IPTp was added to the services currently provided.  The mean
incremental costs per primigravidae were Int$6.59 for very low income strata, Int$7.29
for middle income strata, and Int$12.47 for higher income strata.
This model predicts that the incremental net-benefit of scaling up IPTp from 0% to
90%, to cover an additional 4,860,000 primigravidae12, will be Int$5,783 million
between 2002 and 2015 (BCR of 12.1).  Results according to income strata are given in
table 3.4.
Table 3.4: Costs and benefits of IPTp (2003 Int$)
Income
strata (value
of a YLL)
Additional
PG covered
Total
benefit
(millions,
2002-15)
Total cost
(millions,
2002-15)
Net-benefit
(millions,
2002-15)
Annualised
net-benefit
(millions)
Benefit-
cost
ratio
Low income
(Int$850)
3,294,313 $2,260 $282 $1,978 $152 8
Middle
income
(Int$1,863)
1,191,955 $1,792 $112,899 $1,679 $129 16
High income
(Int$7,250)
373,732 $2,187 $60,603 $2,126 $164 36.1
Calculated from (3), (28), (1) PG = primagravidae
The DCR has a substantial effect on net benefits because it influences the weight of
future treatment failure due to increasing resistance.  Changing the DCR from 3% to 6%
increases net-benefit by 11%.  Standardising the ceiling ratio to Int$3,830/YLL strongly
affects results, giving a total net-benefit of Int$14,567 million for 2002-2015 and a BCR
of 33.9.
Net-benefits may be underestimated if IPTp has an impact on child mortality beyond 28
days.  In addition, the health benefit of IPTp for the mother in terms of reduced anaemia
has not been included (78).
In other ways, the mortality associated with malaria may be overestimated.  As in the
ITN model, all cause mortality can be expected to be lower in wealthier counties, which
would reduce the incremental mortality averted between the intervention and
comparator. Malaria affects birth weight through both pre-term births and retarded
interuterine growth during a full term.  Mortality rates are higher for pre-term birth than
retarded interuterine growth, but it is not clear which mechanism is influenced by SP.  If
IPTp affects only retarded interuterine growth, net-benefits would be lower.
                                                
12 Based on estimates made by the U.S. Bureau of the Census that the number of births in SSA would
increase from 25 million in 1996 to 33 million in 2020
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Switching to ACTs
Based on a previous model (67), we evaluated the net-benefit of a change in policy from
SP to ACT, including the use of dipsticks for diagnosis to ration drugs more efficiently
and combat the spread of resistance.  To account for resistance and to be consistent with
other models, we evaluated this model over a 13 year time frame.
A simple decision tree of the diagnosis and treatment of malaria was used to follow the
possible costs and outcomes of a patient presenting with malaria and receiving first line
treatment.  Costs were attached to the branches of the tree so that a cost would be
estimated for each path that an outpatient could be expected to take.  Cost per individual
outpatient was calculated by multiplying the cost of each branch by the probability that
it would be followed.  The cost per adult treatment with ACT included an estimate of
ACT drug costs (60, 79) and ranged between Int$3.57 and Int$8.57.  The SP cost
(which would be no longer incurred) was fixed at Int$0.50.  We assumed that half of the
patients presenting with malaria would be under five years old, and that they would
receive a half-dose.  As switching drug policy for people already receiving treatment is
likely to use existing distribution and treatment systems, we assumed that no additional
transport, administration, or overhead costs would be incurred.
The decision tree framework is useful because gross costs can be calculated for each
strategy, as well as net costs between them.  Net costs are particularly relevant for this
analysis as ACTs are expected to improve health outcomes significantly.  Reductions in
the number of persistent cases of uncomplicated malaria and the number of cases
developing to severe malaria would lead to lower follow-on treatment costs for
providers.  As severe malaria can lead to hospitalisation, these cost savings can be
substantial, heavily influencing net-benefit.  The annualised incremental cost of using
ACTs instead of SP over a period of 13 years was calculated at Int$2.98 per malaria
patient treated.
We evaluated outcomes according to treatment failure or cure, defined as adequate
clinical response following WHO criteria (80).  If treatment fails, the patient may
develop severe malaria or continue to suffer from uncomplicated malaria.   If severe
malaria develops, they may seek inpatient care, where they will receive intravenous
quinine.  If they seek care with uncomplicated malaria, they may receive a second-line
antimalarial13.  The probabilities of full recovery or death were then estimated, as
reported in Coleman et al. (67).
The probability of treatment failure, F, with a given first line drug, i, at time t was
defined as being dependent on three main inputs.  First, the proportion of malaria
parasites, R, resistant to drug i at time t.  Second, the probability, m, that a patient
complies at the recommended dose with drug therapy i.  Third the probability, p, that
therapy i is effective despite the patient not complying fully with the treatment regimen.
As SP can be treated with a single dose, it can be expected that a high proportion of
patients will fully comply.  However, ACTs must be taken in several doses, and it is
possible that patients will abandon treatment before finishing the full regimen.  In a
Zambian study, 21.2% of patients were non-compliant, with an additional 39.4%
probably non-compliant (81).  We assumed that 85%-95% of patients complied to SP,
                                                
13 It was assumed that amodioquine was the second-line drug to SP, and that ACTs would be read
ministered if ACT was used as first-line.
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and 60%-80% of patients complied to ACT.  In some cases of non-compliance with
combination therapy, only minor underdosing may have occurred and some therapeutic
effect may be experienced.  In the absence of drug resistance, it was expected that ACTs
would be effective in 10-30% of underdosed patients.
We assumed that all patients infected with resistant parasites experience treatment
failure, regardless of whether or not they fully comply with the treatment regimen.
Treatment with drug i at time t may be successful if the patient is not infected with
resistant parasites and fully complies with the treatment regimen; the probability of this
occurring is (1-Ri,t)mI. Alternatively, the patient may be infected with susceptible
parasites but, despite not complying with the treatment regimen, is still cured; the
probability of this occurring is (1-Ri,t)(1-mi)pi. Thus
( ) ( )( )[ ]iitiititi pmRmRF −−+−−= 1111 ,,,         (eq. 5)
defines treatment failure, which simplifies to
( ) ( )[ ]iiititi mpmRF −+−−= 111 ,, .         (eq. 6)
Levels of resistance were modelled using the same logistic function as in the IPTp
model.    The rate at which resistance will grow to ACTs has yet to be observed, and we
assumed that it would grow at one-half the rate of SP based on the arguments outlined
in section 3.214 (figure 3.1).
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Figure 3.1 Effect of resistance on treatment failure (from (67))
The decision tree was used to calculate the probabilities of surviving or dying, which
were converted to expected DALYs per patient.  Estimates were made separately for
patients over and under five years of age, and the total DALYs were calculated as a
weighted average according to each group’s share in the population.  Overall, it can be
expected that this policy change will avert 0.066 DALYs per case each year until 2015.
It has been estimated that children experience 200 million cases of malaria each year in
SSA (61).  If half of malaria cases affect adults in endemic areas, it can be assumed that
                                                
14 The lower level of compliance to ACT makes treatment failure more likely at initial levels of
resistance, despite its higher efficacy.
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twice this number will occur in total (67).  Currently, only about 42% of these cases
receive an antimalarial, implying 168 million treatments needing a different drug.  The
incremental net-benefit of switching to ACT is given in Table 3.5.
Table 3.5: Costs and benefits of changing from SP to ACT (2003 Int$)
Intervention
(value of
DALY)
Malaria
patients
treated
Total
benefit
(millions,
2002-15)
Total cost
(millions,
2002-15)
Net-benefit
(millions,
2002-15)
Annualised
net-benefit
(millions)
Benefit-
cost
ratio
SP to ACT
(Int$1,750)
168,000,000 $251,297 $6,510 $244,787 $18,830 38.6
Calculated from (3), (67), (1)
Increasing the DCR to 6% would decrease net-benefits by 23%.  Standardizing the
ceiling ratio to Int$3,830/DALY would increase net-benefits to Int$543 billion.  Results
are relevant also to countries still using CQ as unit costs for CQ and SP are very similar
and patients are more likely to adhere to SP than CQ (28).
Scaling up ACT coverage
In order to halve the malaria burden by 2015 it will be necessary to scale up
substantially the proportion of people who are treated for malaria (1).  Adapting the
decision tree used to evaluate a change in first-line therapy, we evaluated the net-benefit
of extending ACT treatment to currently untreated malaria cases, to reach a treatment
target of 70%, and including dipstick diagnosis in order to target treatment effectively.
Incremental costs of scaling up coverage can be expected to be much higher than for
switching treatment policy since capacity expansion will be required. Costs include
buildings and equipment, supervision and training, staff salaries, and costs incurred by
individual patients. The incremental costs of scaling up ACT coverage were estimated
at Int$20.21 per additional patient.
The health benefits of scaling up treatment will also be substantial.  People with malaria
that do not receive treatment can be expected to incur 0.310 DALYs, and patients
treated with ACTs average 0.089 DALYs, over a 13 year time frame.  An incremental
0.221 DALYs would be averted per patient.
Given that around 42% of cases in SSA are currently being treated with a malaria drug
(6), if the proportion of cases treated for malaria is scaled up to 70%, it can be expected
that an additional 112 million episodes will be treated each year.    The incremental net-
benefit of this policy change are shown in table 3.6.
Table 3.6: Costs and benefits of scaling up ACT (2003 Int$)
Intervention
(value of a
DALY)
Additional
malaria
patients
covered
Total
benefit
(millions,
2002-15 )
Total cost
(millions,
2002-15)
Net-benefit
(millions,
2002-15)
Annualised
net-benefit
(millions)
Benefit-
cost
ratio
SP to ACT
(Int$1,750)
112,000,000 $157,683 $8,240 $149,443 $11,496 19.1
Calculated from (3), (67), (1)
Increasing the discount rate to 6% would decrease the net-benefit by 17%, and
standardizing the ceiling ratio to Int$3,830/DALY would increase total net-benefits to
Int$337 billion.
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Package of interventions
Net-benefits and benefit-cost ratios for each of the three interventions are summarised in
Table 3.7 in annual terms.  In the absence of evidence on synergies between
interventions, costs and benefits have been simply summed to illustrate the costs and
benefits of the package.
Table 3.7: Costs and benefits of a package of malaria control measures (2003 Int$)
Intervention Per-capita
costs
(annualised)
Total monetary
benefit
(annualised)
(millions)
Total cost
(annualised)
(millions)
Net-benefit
(annualised)
(millions)
BCR
ITNs $30.33 per
child
$18,479 $1,773 $16,706 10.0
IPTp $8.78 per PG $480 $35 $445 12.1
Changing to ACT $2.98 per
malaria case
$19,331 $501 $18,830 38.6
Scaling up ACT $20.21 per
malaria case
$12,130 $634 $11,496 19.1
Total $50,417 $2,942 $47,375 26.9
It should be noted that benefits in this table are valued using ceiling ratios specific to
SSA.  The value of benefits thus reflects the low incomes of SSA. We present results
using a standardized ceiling ratio in the final section to adjust for this.
A notable feature of this analysis, largely neglected to date, has been the inclusion of
considerations of drug resistance.  Although this considerably complicates the analyses,
not least because it requires analysis over time, it provides a more realistic estimate of
costs and benefits.  However, it should be noted that the costs of research into new
drugs has not been included here as a cost.
Success story: KwaZulu Natal, South Africa
Evidence of the cost-effectiveness of different malaria treatment and control strategies
was taken from the South East African Combination Antimalarial Therapy (SEACAT)
study done in the Ingwavuma district in the KwaZulu Natal province of South Africa
(21).  This region is classified internationally as a low-transmission area and malaria is
seasonal.  In the year 2000, this region suffered a particularly severe outbreak of
malaria, with nearly 6,000 cases per month at its peak.   The national malaria
programme was deemed ineffective and immediately changed.
The programme existing in 2000 consisted of insecticide residual spraying (IRS) with
deltamethrin and malaria case management with SP.  In 2002, IRS with a combination
of deltamethrin (60%) and DDT (40%) was introduced, and first line drug treatment was
changed to ACT.  An economic evaluation was conducted to test the cost-effectiveness
of this change in policy at one hospital and 9 clinics between 2000 and 2002.  The
authors separated the effects of ACTs from those of IRS using a Delphi survey of 10
international malaria experts.
The interventions were hugely successful as the facilities saw 21,874 fewer cases of
malaria between 2000 and 2002.  The Delphi survey suggested that ACT was
responsible for averting 36% (range 25%-50%) of these cases.  Assuming that people
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with malaria would otherwise be treated with SP, 0.002 YLLs would be avoided for
each case averted (67).  Valuing each YLL according to the South African GNI
(Int$10,910), the programme would have a monetary benefit of Int$202,798 (range
$140,832 - $281,664).  Int$774,630 were saved due to fewer treatments being
necessary, and the net-benefit of the programme was Int$977,428 (range Int$915,463 -
Int$1,056,294).  Lowering the ceiling ratio to Int$3,830/YLL gives a net-benefit of
Int$845,823.
In addition to being highly effective in averting malaria cases, this programme was cost
saving: South Africa has a relatively well-developed primary care system, where 69%
of people live within 5 km of a clinic.  Publicly provided health care is widely used –
over 93% of patients with malaria sought treatment from one of these clinics, which
were backed by a well-regulated and reliable drug supply (21).
The findings of this study represent programme data, not a controlled trial.  Cost-
effectiveness may be overestimated if other factors, such as changes in climate and
precipitation, contributed to the reduced prevalence of disease.
3.5 Feasibility
Feasibility can be examined according to a number of different dimensions, notably
political, financial, and managerial.  Many aspects of feasibility are common to all three
opportunities, most notably because some of the malaria and HIV/AIDS interventions
require a basic health service system.  Hence the general discussion on feasibility is
located in section 5.5, and the discussion here and in the subsequent HIV/AIDS
feasibility section concentrates on issues specific to these two diseases, including the
extent to which interventions can be successfully delivered where basic health services
are weak.
Political feasibility has changed markedly in recent years with respect to malaria.  A co-
ordinated effort at international level, including the creation of Roll Back Malaria,
culminated in the Abuja declaration.  Malaria was included in the scope of the new
Global Fund for AIDS, TB and Malaria.  An external evaluation of RBM found it to
have been highly successful in global advocacy, and in attracting attention to malaria
control (82).  The evaluation team estimated that international expenditures on malaria
had doubled.  However, there was lack of progress in demonstrating a significant
reduction in the global burden of malaria.  At country level, National Malaria Control
Programmes and National Programme Officers were judged to be weak, and unable to
advocate effectively.  Hence political commitment remains an issue at the country level.
The Abuja Summit called for US$ 1bn a year to help Africa tackle malaria; however,
this request may be an underestimate of the actual resources needed to address the
epidemic effectively.  CMHWG5 estimates, which sought to cost fully the provision of
a package of malaria control measures at local level, estimated that to achieve high
levels of coverage by 2015, $1.5-2.2 billion (US$2002) would be needed a year for
prevention and treatment of adults in SSA, and a further $3.3-4.2 billion for a child
treatment package which included malaria.   Fighting malaria would be less costly than
fighting HIV, which CMHWG5 estimated to cost between $10.1-12.1 billion a year in
SSA by 2015.
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Managerial feasibility can be examined with respect to the three interventions evaluated.
With respect to ITNs, feasibility is dependent on the delivery strategy.  At one extreme,
a strategy of free public distribution is dependent on the existence of an effective basic
heath service network, and a well managed supply pipeline from manufacturers to
health centres.  However, the Tanzanian experience demonstrates that in some settings,
relying on private sector distribution channels and individual willingness to pay,
stimulated by publicly funded social marketing campaigns and encouragement to
manufacturers, can achieve a marked increase in net coverage. From a relatively small
base of 200,000 nets per year in 1994, there has been a dramatic increase to domestic
sales of around 1.5m nets in 200215.  Manufacturing capacity exceeds 4 million nets,
and nets are being exported to other countries in Africa.  The reasons for this expansion
in net production include the positive impact of reductions in taxes and tariffs, and the
effects of demand creation activities undertaken through a variety of small scale
projects, and more recent large scale social marketing activities.   Retail prices have
fallen dramatically, to US$ 1.8 ex factory, presumably reflecting competition, and
possibly also economies of scale operating at lower levels of the distribution system.
There is anecdotal evidence that saturation of urban markets is leading to increased
penetration into rural areas.  The challenge currently faced is how to channel subsidies
to those unable to pay the commercial price.  While as in Tanzania, nets can be bundled
with the initial insecticide treatment, encouraging re-treatment has proved a major
problem in many countries.  This problem will be solved in the foreseeable future by the
introduction of long lasting nets.
IPTp delivery is dependent on an antenatal care (ANC) infrastructure.  In most of SSA
the percentage of primagravidae receiving antenatal care is high.  Although historically
the coverage of malaria prophylaxis of pregnant women in ANC has been very low, this
has in part resulted from lack of attention to this intervention and low adherence to the
previous drug, CQ.  Intermittent treatment using SP improves adherence, which can also
be improved by education of mothers.  Thus except in countries with extremely weak
ANC, this intervention is managerially feasible.  In the future, development of
resistance to SP will threaten this strategy, and research is urgently needed to identify
anti-malaria drugs that are safe to give in pregnancy.
Malaria treatment for children and adults is accessed though both public and private
sectors.  In SSA, given the limited reach and often poor quality of government services,
as much as 60% of treatments may be purchased from the private sector, often local
drug shops and general stores (62).   If the additional cost of ACT is to be matched by
the benefits of reduction in the rate of growth of resistance, it is likely that coverage of
ACTs must be high, and coverage of either of the component drugs given as
monotherapy low16.  This means that not only do public sector services need to be
improved (considered below under section 5.5), but also private sector dispensing
practices must be addressed.  Experiences of how this can be done are accumulating,
and include a combination of consumer education, improved drug packaging, and
retailer training and support  (62).  Franchising and contracting approaches can be used
to structure the implementation of these specific measures, and provide incentives for
good practice.
                                                
15 Kramer personnel communication
16 Otherwise use of the monotherapy will increase the probability of resistance developing and spreading,
and threaten the combination drug
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4 Control of HIV/AIDS
4.1 Identification and description of opportunity
Introductory Statistics
HIV/AIDS affects nearly every country in the world, with more than 90% of infections
occurring in developing countries (83, 84).   Between 2.5 and 3.5 million people died
from HIV/AIDS in 2003, accounting for over 5.1% of all deaths worldwide (85, 86).
Current estimates are that more than 22 million people have died through the course of
the epidemic (11), between 34 and 46 million people are currently living with
HIV/AIDS, and 5.3 million new infections occur each year (86).17  The problem has
reached such a magnitude that it is considered not just a health issue, but a development
issue (87), and most recently a global security threat (88).  The Commission for
Macroeconomics in Health argued that it is ‘a distinct and unparalleled catastrophe’
with the ‘capacity to overturn economic development in Africa and in other regions for
decades’ (51).  There have been recent suggestions that prevalence is lower than had
been thought – for example 22m cases in SSA rather than 26.6m (89)– though still
appallingly high.
Epidemiological Description
The distribution of HIV/AIDS is geographically diverse, and can be classified according
to three stages of the epidemic; nascent, concentrated, and generalized (84).  As large
population studies are expensive and problematic, these definitions rely on prevalence
levels among women attending ante-natal clinics and groups considered to be
particularly at-risk.  These high-risk groups include sex workers, injecting drug users
(IDUs), the military, homosexual and bisexual men, and people already affected by
another sexually transmitted infection (STI).
The HIV/AIDS epidemic can be categorised as nascent, concentrated, and generalised.
The epidemic exists in its nascent stage where less than 5% of individuals in high risk
groups are infected, and less than 1% of the overall population is affected (86). Over 2.3
billion people live in these areas, which include China, Indonesia, Papua New Guinea,
several central Asian republics, the Baltic states, and parts of north Africa (84).  The
epidemic is in its concentrated stage where it has become established among high-risk
groups (over 5%), but not amongst the general population.  Concentrated epidemics
exist in much of Latin America, several central Asian republics, SSA, and around heroin
networks in Southeast Asia and Pakistan.  The generalized form of the epidemic exists
where over 5% of the overall population is affected (84).  Southern and eastern Africa,
along with a few countries in west Africa, are currently suffering this stage of the
epidemic.  In some areas the overall prevalence of infection may reach as high as 40%,
as in Botswana (86).
While the HIV/AIDS epidemic has yet to be fully described, solutions lie in addressing
the risk factors associated with its spread.  A large proportion of HIV is transmitted
through the sex industry, especially in areas where condom use is low.  Without
protection from condoms, individuals already infected by other sexually transmitted
                                                
17 http://www.whitehouse.gov/onap/facts.html
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infections (STIs) are particularly vulnerable to HIV infection.  This risk factor is
especially important in sub-Saharan Africa, where 90% of HIV infections are
transmitted through heterosexual sex.  Sex between men is another contributing factor
to HIV spread, particularly in Latin America. Intravenous drug use (IDU) spreads the
epidemic among users during nascent stages of the epidemic.  These individuals then
spread the virus further by infecting their sexual partners (86) (84).
Microeconomic impact
At the household level, HIV/AIDS can impose heavy cost burdens, undermine assets
and livelihoods and be a cause of impoverishment.  In many developing countries this is
exacerbated by households’ poor access to health services, and the high costs (both
direct and indirect) of seeking treatment.
The costs of an adult death constitute the key microeconomic impact of the HIV/AIDS
epidemic.   Unlike malaria, HIV can affect poor and rich alike, though it might be
expected that over time richer people would be more able and likely to adapt their
behaviour.   A number of household studies in subsistence economies have sought to
measure the impact of an AIDS death, and to study how households cope (90, 91).  The
effects of HIV/AIDS are felt on two key farm parameters.  First, household labour
quality and quantity are reduced, initially as the infected person is less productive, and
subsequently with their death.  This is exacerbated when there is more than one infected
person in a household, which is not unusual given the nature of transmission.  In
addition, household time is diverted to care for the sick person.  For example, in the
Thai study, 13% of school aged children in families with an AIDS sufferer were
withdrawn from school to support the family (90); interruption of education, to care for
parents, contribute to household income or food needs, or because of lack of money for
school fees, was also found in the Ugandan study (92).  Secondly, HIV/AIDS affects
the availability of cash income.  Financial resources have to be diverted to pay for
medical treatment and funeral costs; since the disease is a chronic one, such costs can
be very substantial and often will require sale of assets.  In the Thai study, 60% spent all
their savings as a result of the AIDS infection, and on average out of pocket medical
expenditure from the beginning of the illness until death amounted to 6 months of
average total household income (90).  In the study in Tanzania, household medical
expenses tended to be much higher for AIDS than for other causes of death (91).
Funeral expenses are also a substantial expense, in the Tanzanian study amounting to
about as much as medical care.  Such diversion of expenditure can be at the expense of
food consumption where resources are very limited.
Shortage of labour may lead households to change the mix of crops, shifting from cash
to subsistence crops, or reduce the area under cultivation (92).  In the longer term,
households may dissolve or be reconstituted as children are fostered, orphaned or die,
and spouses remarry or migrate.
However, households do not all respond in the same way, or suffer the same level of
costs.  Studies demonstrate that the impact of AIDS varies according to three sets of
characteristics: those of the dead individuals, such as age, sex, and income; those of the
household such as composition, assets, and source of livelihood; and those of the
community, such as support systems and the availability of resources (84).  In general,
studies have suggested that households can be surprisingly resilient to the costs of
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AIDS, precisely because of coping mechanisms: altering household composition (eg
sending children to live elsewhere, or inviting adult relatives into the household);
drawing down savings or assets (for example 41% of households with a death in the
Thai survey reported selling land; and 60% of households in the Uganda study sold
property to cover care costs); and drawing on assistance from other households (for
example local associations may be set up specifically to assist community members
with AIDS).  In an African context, labour intensive farming systems with a low level
of mechanization and agricultural inputs are said to be particularly vulnerable to the
impact of AIDS (92).
As might be expected, the economic impact of AIDS is larger in poorer households.   In
the Thai study the lowest income and the least educated engaged in agricultural work
were least able to cope (90).  In the Tanzanian study, per capita food consumption
dropped by 15% in the poorest 50% of households during the 6 months following the
death, which would be likely to increase levels of malnutrition (91).  Where the death
was of a woman, children had lower school enrolment rates and were more likely to
undertake activities normally done by women, such as cooking.
In addition to imposing costs on households, HIV/AIDS increases demands on
government health care services since it increases demand for health care amongst
adults, usually a section of the population where health care demands are relatively low.
In addition, several studies suggest that adults with AIDS use more health care prior to
death than those who die of other causes (84).   Since HIV/AIDS also reduces the
supply of health care, notably by reducing the supply of health care workers, the result
is that health care facilities become swamped by chronic care patients.   For example,
the percentage of beds occupied by HIV-positive patients in 6 referral hospitals in
developing countries with large epidemics was over 50% in 5 of the 6, and there was
evidence that non-HIV positive patents were less likely to be admitted (84).
The consequences of HIV/AIDS for the business community have recently attracted
increased attention (93, 94).  AIDS not only increases absenteeism in people stricken by
the virus, but also in those that must provide care for them.  AIDS deaths increase staff
turnover, and increase costs of re-assigning and training workers.  Production processes
become disrupted, and output of firms is decreased as a result.  Firms are required to
allocate more resources towards medical benefits for the sick and pensions for their
dependents after they die.   These effects are discussed further below.
Macroeconomic impact mechanisms
The mechanisms through which HIV/AIDS affects national economies are as yet poorly
understood, and the variety of approaches and assumptions have lead to widely differing
estimates of impact. Macroeconomic models, discussed later in this section, have sought
to quantify the detrimental effect of the epidemic on productivity and economic growth,
often summarised as the impact on total and per capita Gross Domestic Product (GDP).
Making predictions about the effect of a hypothetical alternative to an existing scenario
is a fundamental challenge of economic modelling.  For areas where no intervention has
been implemented, the impact of intervening must be estimated. Likewise, in areas
where measures have been taken to combat HIV/AIDS, the disease burden in the
absence of these measures must be approximated.  Currently, no method for modelling
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the macroeconomic effects of HIV/AIDS has been agreed upon; however, a review of
existing work illustrates what progress has been made.
The question of how the costs and benefits of HIV/AIDS can be most appropriately
quantified is fundamental in the macroeconomic modelling of the epidemic.  The
epidemic has a complex impact on economic growth since the majority of HIV related
deaths are amongst people of working age.  In the medium term, the size and
composition of the labour force are affected mainly through increased mortality rates,
whereas in the long term, declining birth rates also contribute to the loss of workers
(93).  Early models assumed that the economy would sustain these losses, as increased
mortality would relieve pressure on existing land and physical capital.  The argument
supporting this assumption was that unemployment levels are currently very high in
Africa, and immigrants often fill vacant positions. As a result, models created between
1980 and 1992 found that mortality would have little effect on output per head (11, 95,
96).  However, more sophisticated approaches have recently been developed,  and have
found that reductions in the labour force have a powerful impact on GDP (93, 97).
The decimation of the labour force has economic costs in itself in terms of productivity
and training in all areas of the public and private sectors.  Aside from the impact of
higher mortality rates, surviving workers are less productive as they spend more time
away from work either caring for the sick or coping with their own infection.  As
experienced workers are eliminated from the labour force, new staff must be recruited
and trained.  These effects are likely to be especially important in the education sector
as education is a strong determinant of the productivity of future generations. On the
supply side, fewer teachers are available.  For example, in Zambia the death rate of
school teachers exceeds the annual capacity of teacher training colleges (96).  Further,
governmental funds allocated towards education are reduced. The demand for education
is likely to become weaker, especially amongst vulnerable groups, as people become
less certain about their future.
The structure of the household is another consideration that must be taken into account
when measuring macroeconomic effects. The epidemic creates unprecedented numbers
of full and partial orphans, disrupting traditional channels of community support and
organization.  Bell and colleagues (95) evaluated these effects by constructing a model
that considered two family structures, nuclear and ‘pooling’. In a ‘pooling’ family
structure, the extended family raises its children in a cooperative effort.  Where this
collective responsibility is not taken, transmission of knowledge vital for children to
become productive members of society is weakened.  When these children become
adults, their capacity to raise their own children well is severely reduced.
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Spending on HIV/AIDS prevention was found to be much more likely to reduce the
impact of the epidemic on the South African economy if resources were pooled than if
people were organized into nuclear families (95).  If society is structured around nuclear
families, these losses can be alleviated somewhat by educational subsidies.  However,
these subsidies are not as effective as family reorganization, as figure 4.1  shows.
Calculated from (95)
From the perspective of government expenditure, fewer resources are available for
investment in non-health related sectors as they are directed towards strategies that
attempt to manage the epidemic.  Governmental revenue declines as individual
productivity decreases and levels of taxable income drop.  As people change their
spending patterns, and have less disposable income to save and spend, tax revenues
decline further.
Haacker (93) demonstrated that the economic impact of HIV/AIDS is exacerbated when
it is considered from the more realistic perspective of an open-economy, as compared to
a closed-economy where the relationship to the rest of the world is ignored.  In an open
economy, the rate of return on domestic assets is linked to world interest rates, and
foreign investors will be less inclined to risk ventures in that country as it becomes less
productive.  In addition, residents will have more incentive to invest abroad. Mortality is
considered identically in each scenario, but reductions in the capital/labour ratio have
greatest impact in the open economy.  These assumptions have powerful effects on
predictions about GDP.  Depending on which perspective is taken, predictions about
whether economic gains or losses can be expected are reversed.  In Botswana, closed-
economy assumptions predict that national GDP will rise by 9.6% in the long term;
open-economy assumptions predict a 3.3% loss (93).
McPherson (96) has argued that the macroeconomic impact of HIV/AIDS predicted by
current models is likely to be grossly understated.  With the exception of Zerfu et al., no
model has considered effects from disruption to agricultural production and food
security (98), yet maize production in northern Zambia has decreased by 71% in the last
decade, and 40% of positions in the Malawian Ministry of Agriculture are vacant, so
these disruptions can be expected to be severe (96).  Further, current models assume an
early peak in the epidemic, which is unlikely to occur given the already devastated
condition of many affected countries (96).
Figure 4.1: Long-run economic costs of AIDS in South
Africa
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Regional impact estimates
Middle East and North Africa: For the Middle East and North Africa, a macroeconomic
model was coupled with an HIV diffusion model that considered spread through both
sexual transmission and intravenous drug use.  Three types of labour were considered:
skilled, unskilled, and unemployed.  The model found that the most severe impact of the
epidemic occurred on unskilled and unemployed groups.  By 2025, it predicted that the
epidemic would reduce the total GDP of North Africa by 35% of today’s GDP,
compared to projections of what would occur in the absence of HIV/AIDS (97).  The
expected losses borne by 9 countries in this region over this period are summarized in
Table 4.1.
Table 4.1 Effects of HIV/AIDS on national GDP 2000-2025
2000 GDP
(in millions)
Percent loss
No intervention
Monetary loss
(in millions)
Algeria $186,900 36.20% $67,658
Egypt $222,190 44.30% $98,430
Iran $364,400 33.60% $122,438
Jordan $18,684 27.90% $5,213
Lebanon $17,950 26.30% $4,721
Morocco $97,991 33.20% $32,533
Tunisia $58,574 45.50% $26,651
Yemen $13,954 31.40% $4,382
Calculated from (97)
Sub-Saharan Africa: Haacker (93) devised a model for SSA that assumed HIV
prevalence remains in a steady state, in order to examine its impacts on the macro
economy.  This assumption can also be justified on the basis that the prevalence of HIV
in many countries may be approaching its natural limit.  The model used evidence on
the demographic impact of HIV from UNAIDS and the US Bureau of the Census to
predict the effects of the epidemic at end-1999 levels on companies and disaggregated
areas of the public sector.  Effects on GDP were measured both from the perspective of
an open economy and a closed economy.  From the perspective of an open economy,
the following losses to per-capita GDP can be expected in the long term (Table 4.2).
Table 4.2: Effect of HIV/AIDS on long-term
GDP: No action taken
Country Percent loss
(per capita)
Botswana 3.2%
Lesotho 2.1%
Malawi 1.4%
Mozambique 1.2%
Namibia 1.8%
South Africa 1.8%
Swaziland 2.3%
Zambia 1.8%
Zimbabwe 2.3%
Calculated from (93)
4.2 Alleviation of the challenge - interventions
A complete package of services to alleviate the impact of the HIV/AIDS epidemic must
include both treatment and preventive interventions (1). Whilst preventive measures are
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crucial as AIDS is currently an incurable disease, a strong moral argument has been put
forward to justify the inclusion of measures to treat the 34-46 million people currently
infected by the virus (86).  However, as ARV prices are changing rapidly and their
effects in the developing world are highly uncertain, we have considered here primarily
preventive interventions.
Nascent epidemic
In countries where the epidemic is nascent, treatment measures are expected to be a
negligible component of overall costs and benefits as less than 5% of people in high-risk
groups would be infected and condom distribution and expanding safe access to needles
are considered the major preventive measures (97).  However, the relative importance of
intravenous drug use and sexual transmission as risk factors varies according to
geography.   Therefore, programmes need to be tailored to specific country needs.
Concentrated epidemics
Concentrated epidemics require both treatment and preventive interventions to address
fully the health crisis, most notably a set of interventions specifically targeted to high-
risk groups (such as IDUs, sex workers, and their clients).  As an illustration, in 1989,
the Ratchaburi province in Thailand introduced an initiative focused on prevention
commonly known as the ‘100% condom programme’, which expanded nationally by
1991 (20).  In this programme, condoms were provided free of charge to brothel
workers, who were required to refuse sex to anyone who refused to wear them.  If an
infection was detected in any of these workers, police had the right to close the brothel.
Further, information was obtained from men who presented to governmental health
clinics with STIs to trace their infection back to its source.  Non-governmental
organizations provided training and empowered experienced sex workers to train
younger ones to negotiate condom use by their clients.  Public health checks were also
provided free of charge to these workers.  The initiative directed at brothels was
supplemented by a TV and radio campaign to warn men of the dangers of visiting
brothels and not wearing a condom.
Generalised epidemics
A programme to address generalized epidemics would include many of the same
interventions as in a concentrated epidemic, but they would be implemented on a wider
scale.  Creese et al (2002) provide a standardized review of the effectiveness and cost-
effectiveness of HIV/AIDS interventions in sub-Saharan Africa (interventions are listed
in section 4.4).
Stover and colleagues (100) designed a model to determine if the Declaration of
Commitment, made by the United Nations General Assembly Special Session
(UNGASS) in June 2001, to reduce the prevalence of HIV/AIDS by 25% by 2010 could
be met.  From a review of literature on effectiveness, they evaluated a general package
of preventive interventions that should be implemented in low-and middle- income
countries to combat the epidemic (table 4.3).
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Table 4.3: UNGASS HIV/AIDS recommendation
Prevention Interventions
School-based AIDS education
Peer education for out-of-school youth
Outreach programmes for commercial sex workers and their clients
Condom social marketing
Treatment for STIs
Public sector condom promotion and distribution
Voluntary counselling and testing
Workplace prevention programmes
Prevention of mother-to-child transmission
Mass media campaigns
Harm reduction programmes
Outreach programmes for homosexual men
Source (100)
For some of these interventions (youth education programmes, social marketing
schemes, workplace prevention programmes, harm reduction programmes, and outreach
programmes for homosexual men) evidence on effectiveness is very limited.
4.3 Side effects
Positive side effects
HIV/AIDS interventions include both those focused on the sick individual, and those
aimed at changing sexual practices and lifestyles within the household, amongst IDUs,
within society more generally, and within the commercial sex trade.  They are thus
likely to have many beneficial side effects.  Moreover, some of the interventions are not
specific to HIV/AIDS, and provide protection against other diseases.
Examples of beneficial side effects include:
• Increased control of fertility through greater availability of condoms
• Reduced incidence of other STIs
• Better management of other STIs and TB
• Increased access to life saving blood transfusion
• Reduced transmission of disease through blood transfusions
• Reduced domestic violence as result of improved education on sexual health and
support to women (101)
• Better educated youth as a result of school health education programmes
• Strengthened disease surveillance and epidemiological capacity at international and
national levels.
Negative side effects
Comments above on the adverse effects of medicines and vaccines apply also here.
However, there are some concerns specific to HIV, especially that of drug resistance,
specifically in countries where controls are lax and affordability is low.  Supply and
resource constraints have encouraged practices such as the use of single-dose nevirapine
to treat pregnant women, which has been shown to cause resistance in as many as 75%
of women treated (102).  The Global HIV/AIDS programme of the World Bank has
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collaborated with other international bodies to make recommendations for how to
rationally manage ARV programmes18, and several initiatives are showing success in
lowering the price of drugs (103).
4.4 Economic evaluation
Four approaches were taken to assess the costs and benefits associated with services
proposed to address the HIV/AIDS epidemic:
1. Findings on the potential macro-economic impact of preventive measures in the
Middle East and north Africa are reported, to exemplify benefits for countries in the
nascent stage of the epidemic.
2. The costs and benefits from Thailand’s response are estimated, to represent a
successful programme implemented in a country in the concentrated stage of the
epidemic.
3. Benefit cost ratios are calculated for the interventions in SSA.
4. The overall costs and benefits are estimated of the package of interventions
advocated by UNGASS for low- and middle-income countries.
Nascent epidemic package
Robalino et al. (97) found that expanding condom use by 30% and access to safe
needles for IDUs by 20% would prevent losses to the economy between 2000 and 2025
as high as 20% of 2000 GDP (Table 4.4).
Table 4.4: Net benefit in terms of 2000 national GDP by 2025 (2003 Int$)
     Implement immediately          Five year delay
Country Percent loss
averted
Monetary loss
averted
(in millions)
Percent loss
averted
Monetary loss
averted
(in millions)
Algeria 20.40% $38,128 14.70% $27,474
Egypt 27.50% $61,102 19.20% $42,660
Iran 20.60% $75,066 14.40% $52,474
Jordan 15.50% $2,896 11.20% $2,093
Lebanon 16.80% $3,016 11.80% $2,118
Morocco 20.10% $19,696 14.00% $13,719
Tunisia 30.40% $17,806 22.30% $13,062
Yemen 2.20% $307 -1.80% -$251
Figures calculated from (97) and (3)
However, if this intervention is delayed by as few as five years, the results could be
disastrous.  Hesitation could make as much as half of the economic decline unavoidable.
Historical examples corroborate the benefits of acting early.  For example, the gay
population in the US and the national initiative in Uganda have shown remarkable
success in preventing the epidemic from spreading (104).
Macroeconomic estimates of the impact of HIV/AIDS interventions are too limited for
regions with higher prevalence, so we did not apply this approach elsewhere.
                                                
18 Provision of ARV  therapy in resource-limited settings: The challenges of resistance and adherence:
Global HIV/AIDS Program of the World Bank, 17-18 June, 1993
http://www.unaids.org/EN/other/functionalities/Search.asp
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Concentrated epidemic package
Brown (20) estimated the number of HIV infections that were averted in Thailand’s
100% condom programme.  In the worst-affected areas in northern Thailand, the
number of new HIV cases fell five times between 1991-1993, and the number of new
STIs fell ten times between 1991-1995.  While 4% of new Thai military conscripts had
HIV in 1993, only 0.5% were infected in 2001.  Overall, the number of new cases of
HIV in Thailand fell from 142,819 in 1991 to 25,790 in 2001, ultimately even reducing
the incidence in sex workers (20, 104).  Based on these figures, Brown estimated that
200,000 infections were averted between 1993-2000.
The costs of the programme were borne both by the private sector and by the
government (20).  The private sector financed information campaigns broadcast through
the media costing Int$160 million19.  The cost of government programmes aimed at
brothels rose from Int$11,588,769 in 1991 to Int$93,369,040 in 1996.  We assumed that
the cost of the programme grew linearly during this period, and remained constant
between 1996 and 2000.  Discounted at 3%, this programme cost Int$1,738 m 1993-
2000.  ANB and BCR are shown in Table 4.5.
Table 4.5: Costs and benefits of Thailand’s 100% condom programme 1993-2000 (2003 $Int)
Number of
cases
averted
Total benefit
(millions)
Total cost
(millions)
Net-
benefit
(millions)
Annualised
net-benefit
(millions)
Benefit-
cost
ratio
100% condom
programme
200,000 $25,925 $1,738 $24,186 $3,455 14.91
Figures based on (20)
Increasing the discount rate to 6% decreased the net-benefit to Int$22,162 million.
Standardizing the ceiling ratio to Int$3,830 reduced the net-benefit to Int$14,199
million, and the BCR to 9.17.
Interventions in SSA
Microeconomic studies have shown that most individual interventions for combating
HIV are highly cost-effective (105).  Table 4.6 demonstrates this, together with
estimated benefit cost ratios.
Many of these figures are likely to underestimate the cost-effectiveness (and benefit cost
ratio) of the interventions.  For example none of the studies that evaluated preventive
measures against vertical transmission considered the knock-on effects on horizontal
transmission.  The effects of ARV therapy may be underestimated as transmission may
be reduced through the reduction in viral loads; also prices are falling rapidly.
Several other interventions not included in this review show promise of being highly
cost-effective measures against HIV.  Microbicides are being developed that women
could use discreetly to protect themselves in the absence of condom use, and may be
available as soon as 2007.  It has been shown that their benefits in terms of productivity
gains and direct cost savings to the health system would be substantial, and are robust to
wide variations in assumptions (106).
                                                
19 We assumed that this programme cost $25.5 million each year.
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Table 4.6: Benefit cost ratios of interventions for SSA
Cost per DALY averted
Prevention
Benefit
Cost Ratio
Reported
(2000 US$)
Adjusted
(2003 Int$)
Condom distribution plus STD treatment for sex workers 466 $1 $4
Female condoms targeted to: Sex workers 39 $12 $45
   High-risk women 10 $48 $180
   Medium risk women 5 $99 $372
Blood safety
Hospital based screening 93 - 466 $1 - $5 $4 - $19
Strengthening blood transfusion services
Defer high risk donors 93 - 466 $1 - $5 $8 - $11
Test and defer high risk donors 155 - 233 $2 - $3 $8 - $11
Rapid test 155 $3 $11
Improved transfusion safety with outreach 39 - 47 $10 - $12 $38 - $45
Improved blood collection and transfusion 11 $43 $162
Peer education of sex workers 67 - 116 $4 - $7 $15 - $26
Prevention of mother-to-child transmission
Single dose nevirapine (universal) 52 $9 $34
ZDV Petra regimen 52 $9 $34
ZDV CDC Thai regimen 6 - 14 $33 - $75 $124 - $282
Formula recommendation 4 $131 $492
Breastfeeding 3 months 3 $171 $642
Formula provision 2 $218 $819
Breastfeeding 6 months 1 $731 $2,748
Diagnosis and treatment of STIs 39 $12 $45
Voluntary counselling and testing 21 - 26 18 - $22 $68 - $82
Treatment and care
Short course TB treatment for new sputum-smear positive pulmonary patients
TB Ambulatory care: Malawi, Mozambique, Tanzania ’91 155 - 233 $2 - $3 $8 - $11
      Uganda, 1995 116 - 233 $2 - $4 $8 - $15
      South Africa, 1997 29 - 58 $8 - $16 $30 - $60
IUATLD model: Uganda 1995 116 - 155 $3 - $4 $11 - $15
Malawi, Mozambique,   Tanzania, 1991 58 - 116 $4 - $8 $15 - $30
South Africa, 1997 7 - 14 $34 - $68 $127 - $256
Community based DOT 22 - 33 $14 - $21 $53 - $79
Co-trimoxazole prophylaxis for HIV and TB patients 78 $6 $23
Home-based care for people with AIDS
Community based programme: Tanzania 6 $77 $289
      Zambia 5 $99 $372
Health facility based programme: Zambia, 1994 1 $681 $2,560
           Tanzania, 2000 1 $786 $2,955
          Zimbabwe, 1998 0.3 - 0.9 $469 - $1230 $1,762 - $4,624
Preventive therapy for TB: Isoniazid 6 months 3 $169 $635
Rifampicin plus pyrazinamide 2 months 2 $282 $1,060
Isoniazid plus rifampicin 3 months 2 $288 $1,082
ARV for adults:   Senegal and Cote D'Ivoire, 2000 0 $1,100 $4,135
South Africa, 2000 0 $1,800 $6,766
Figures based on (105)
When interventions are packaged according to those that complement each other, the
cost effectiveness improves further.  A recent study shows that integrating TB and HIV
services can be done for $1 per person under favourable assumptions (107).  Further, the
cost effectiveness of many interventions has been shown to improve as programmes
mature.
Overall package for HIV prevention
The model developed by Stover and colleagues (100) estimated baseline HIV
prevalence in countries with generalised and concentrated epidemics according to the
size of risk group, current practice, and degree of sexual mixing. With no intervention,
they predicted that 45.4 million new infections would occur between 2002-2010.
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Evidence on the effectiveness of interventions (Table 4.3) to limit the spread of the
epidemic was taken from 86 studies found through a literature review.  Their
effectiveness was defined in terms of their impact on five behaviours: condom use,
treatment seeking behaviour for STDs, number of sexual partners, age at first sexual
intercourse, and sharing of potentially infected needles.  They then estimated costs and
outcomes according to coverage levels, many of which varied with prevalence.  In total,
their model predicted that 63% of infections would be averted if an expanded response
costing US$58.77 were put in place.
We applied an estimate for the number of YLLs lost per HIV infection (23.08), and a
monetary value per YLL lost for the countries included (Int$4,460), to calculate costs
and benefits (Table 4.7).
Table 4.7: Cost and benefits of the UNGASS package of interventions for middle and low- income
countries (2003 Int$)
New
Infections
Baseline
2002-10
(millions)
New
Infections
Package
2002-10
(millions)
Infections
averted
2002-10
Benefits
(millions,
2002-10)
Costs
(millions,
2002-10)
Net benefit
(millions,
2002-10)
Annualised
net benefits
(millions)
Benefit-
Cost
Ratio
45.4 16.9 63% $2,934,148 $58,760 $2,875,389 $359,423 49.9
Figures based on (100) and (3)
Table 4.7 shows that the implementation of the UNGASS package of HIV/AIDS
interventions is substantially beneficial.  When the value of a YLL is lowered to
Int$3830, the net benefit decreases to Int$2.5 trillion, with a benefit-cost ratio of 42.9.
Stover et al. (100) stress that the full impact of their programme is achievable only in
the presence of strong care and support programmes, and with political commitment to
its implementation.  More infections are preventable epidemiologically in countries
where the epidemic is growing rapidly, such as China and Cameroon, than in countries
where it is stable or declining.  With full effect, 33% of global infections would be
prevented in China and India alone, with 40% prevented in SSA.
4.5 Feasibility
A successful battle against the HIV/AIDS epidemic requires political and social
commitment at all levels.  This has been developing slowly – as evidenced by the high
levels of prevalence in much of SSA, and the relatively few countries which are known
for their high commitment to control (such as Uganda and Senegal).  HIV/AIDS
confronts countries with a unique challenge, since major routes of transmission include
those which are illegal, or at least judged morally unacceptable.  To the extent that the
transmission route has to be openly acknowledged in order for it to be addressed, this
poses great challenges to countries reluctant to accept, for example, that homosexual
relationships are widespread in prisons, or that all levels of society frequent sex-
workers.  Commitment can take the form of government support to public health
workers, such as meetings set up by the police between public health workers and
brothel owners (20), and clear public messages. It has been argued that the impact of
these measures is greatest when the public is actively involved in spreading these
messages through the community because people are more likely to internalise the
message and change their behaviour (104).
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For the HIV/AIDS epidemic to be confronted effectively, financial resources from both
higher- and lower-income countries must be increased. The total UNGASS package
would cost US$9.2 billion annually by 2005 to provide the expanded response in low-
and middle-income countries (100).  Currently, the Global Fund for AIDS, TB and
Malaria provides most of the world’s funding to fight AIDS, and has allocated US$2-3
billion towards efforts to control HIV (1).  Donor support has been increasing at an
unprecedented level, with the Bill and Melinda Gates Foundation recently increasing its
pledge to fight HIV/AIDS in India to US$200 million (103).  Other organizations, such
as the Clinton Foundation, are successfully negotiating lower prices for ARV
medications (103).  Since 2000, the cost of antiretroviral regimens has fallen from an
annual US$10,000 per patient to US$300 (108).  Considering that the PPP adjusted
Gross National Income of OECD countries was $25.6 trillion in 2002, full support for
the UNGASS package would require these countries to donate 0.04% (109), a share that
has been judged feasible (51, 110).
Further investment is needed to improve technology to supplement available
interventions.  Currently, there is no cure or vaccine that would provide protection
against the HIV virus.  As previously mentioned, a microbicide that women could use
secretly before sex to protect themselves against infection could be available by 2007.
Lines of responsibility must be drawn for intervention programmes to be effective.
Placing local authorities in charge of promoting awareness and delivering services
increases coverage to marginalised groups and raises awareness. Non-state providers
have an important role in supplementing government health services.  In Uganda, NGOs
such as TASO have been successful in promoting awareness through their work with
faith-based organisations (104).  In India, autonomous AIDS control societies have been
set up through which public funds for HIV/AIDS services are channelled (111).  They
appear to offer an efficient means of working around the slow Indian state bureaucracy.
Countries and organisations need to ensure that information is continuously collected
and analysed for intervention programmes in order to learn from previous mistakes and
improve effectiveness and efficiency. AIDS surveillance in Thailand and Uganda
allowed these countries to monitor the status of their epidemics, and has been
recognised as a major factor contributing to their successes (104) (20).
General issues of feasibility of implementation are reviewed in section 5.5.
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5 Strengthening basic health services
5.1 Identification and description
While the opportunity to scale up basic health services is inclusive of the first two, it
provides a comprehensive perspective of the challenge posed by communicable disease
in the developing world, as well as including other common conditions.   The great
majority of health interventions depend for successful and sustained implementation on
an infrastructure of basic health services, consisting of community based services,
health centres, and local hospitals offering inpatient care.   Such a service infrastructure
has also been referred to as primary health care (PHC), or a district health system.
Relative to other forms of medical care, PHC can be argued to be the most accessible,
least costly, and best equipped method to provide effective care for the conditions that
most affect global health (112).  Theoretically, it is estimated that primary care is able to
address 90% of health care demands.  Although recent international initiatives have
tended to be disease or programme specific (eg Roll Back Malaria, the Global Fund for
HIV, TB and Malaria, GAVI -Global Alliance for Vaccines and Immunisation; 3 by
520), they all acknowledge their reliance on basic health services.  Moreover, there are
historical experiences where a strong public health role in health has been related to
health outcomes that are much better than might be expected at low levels of income
(for example Cuba, Sri Lanka) (113) (114)21.
Two types of evidence are available on the costs and benefits of expanding health
services: evidence from cross-country analyses of the relationship between health
expenditure and health gains; and estimates of the costs and health benefits of packages
of interventions.
Regression analysis has been used to measure the effect of economic inputs on health
sector outputs in terms of elasticities.  To make this link, health must be defined in
quantitative terms, and a proxy measure is used such as under-five mortality, maternal
mortality, underweight among children under 5, and disease-specific mortality.  Public
spending in the health sector is commonly used as an independent variable.  An
advantage of this approach is that it seeks to measure the link between expenditure and
health while controlling for other factors that contribute to national health status, such as
poverty and education.  While an often cited study found that government spending had
a small and insignificant impact on under-5 mortality (115), recent analyses are
beginning to find specific effects on population subgroups (116).  For example, Gupta
and colleagues (117) found that spending had a significant impact on child mortality,
specifically benefiting population groups living on less than two dollars per day.
There have been several efforts to identify a package of priority interventions to be
delivered through local health services, using some mix of criteria including magnitude
of the burden, availability of interventions, and cost-effectiveness.  These efforts include
the World Development Report 1993 (118) (its list is reproduced in section 5.2), Better
Health in Africa (119), the World Health Report 2000 (112, 120), and the CMH WG5
(1).  In general, these efforts identify very similar packages.
                                                
20 Providing anti-retrovirals to 3m people by 2005
21 though good nutrition and education also contributed to these health gains
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5.2 Alleviation of the challenge - interventions
Studies estimating the relationship between increased health sector expenditure and
improved health make no assumption on specific interventions: health expenditure is
increased in proportion to current patterns.
For a package of interventions to strengthen basic health services, we have chosen to
use the WDR 1993 package because its DALY benefit was estimated and the package is
still relevant.  Table 5.1 lists the interventions in the package.  In general, the
interventions make few demands on high level care, with the required hospital resources
consisting of a capacity for emergency surgery, blood transfusion, and treatment of the
more severe cases.
Table 5.1: The WDR 93 minimum health package
Clusters of interventions Main disease conditions addressed
Public Health
Expanded programme on
immunization
Measles, poliomyelitis, tetanus, whooping cough, yellow fever,
hepatitis B
School health programme Intestinal worms
AIDS prevention programme Sexually transmitted diseases and AIDS
Tobacco and alcohol control
programmes
Lung cancer, cardiovascular disease, cirrhosis, injuries
associated with alcohol abuse
Other public health programmes
(including family planning, health,
and nutrition information)
These are not disease specific
Clinical
Short course chemotherapy for
tuberculosis
Tuberculosis in adults
Management of the sick child Diarrhoeal diseases, pneumonia and other respiratory
infections, malaria, measles, and severe malnutrition
Prenatal and delivery care Perinatal mortality and morbidity, complications of pregnancy
and delivery, low birth weight, unwanted pregnancies, and
congenital syphilis and gonorrhea
Family planning Perinatal and infant mortality and maternal mortality and
morbidity
Treatment of sexually transmitted
diseases
AIDS, syphilis, gonorrhea, Chlamydia, and other sexually
transmitted diseases
Limited care (mainly for adults) Pain control, infection and minor trauma treatment, and advice
to reduce chronic diseases
5.3 Side effects
Positive side effects
The existence of a well functioning system of basic health services may have positive
side effects in providing a visible demonstration of the effectiveness of government, and
in improving relationships between the government and local people.
Achieving the MDGs related to health will be vital for making gains in other MDGs.
As outlined in Figure 2.1, health influences income, nutrition, and access to resources,
and can be expected to be an important component of halving the proportion of people
who live on less than one dollar per day.
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Negative side effects
Comments in earlier sections on the adverse effects of drugs and vaccines apply also
here.  Drugs and vaccines used in basic health services have mostly been used for many
decades, so their safety profiles are well known.
5.4 Economic evaluation
We estimated the costs and benefits of scaling up basic health services drawing on the
two sources of data mentioned above: evidence of the relationship between health
expenditure and health gains; and estimates of the costs and health benefits of the
package of interventions recommended in the 1993 World Development Report.
Increased overall health expenditure
According to the elasticities in their model, Gupta and colleagues (117) estimated the
expenditures necessary for a cohort of countries to reach the International Development
Goal (subsequently adopted as an MDG) to reduce child mortality by two-thirds by
2015.  These countries were Heavily Indebted Poor Countries (HIPCs) approved for
further aid from the International Monetary Fund (IMF) and World Bank in mid-2001,
as they found that it would be especially crucial for these countries to increase
preferential spending on the poor for the MDGs to be met.  Assuming that  income and
education levels remained constant, they estimated that public spending on health would
need to increase from an average of 2% of GDP in 1999 to 12% of GDP in 2015.
We quantified the expenditure for 13 of these countries assuming that spending
increased at a constant rate from levels of GDP22.  Between 1990-2001, GDP grew by
3.4% in low income countries (121) and we assumed that this pattern would continue to
2015 (66).  Assuming that additional health expenditures would increase linearly
between 1999 and 2015, incremental expenditure was calculated and discounted.
We calculated benefits by projecting levels of child mortality into the future, decreasing
linearly at an annual rate of 2.67% from a rate of 157 deaths per 1,000 children in 1990,
in order to reach the goal by 2015.  Deaths avoided were calculated by subtracting this
trajectory from a baseline scenario in which child mortality remained constant at 1990
levels.  Each child death was associated with 28.41 YLLs, and valued in monetary terms
according to the average GNI for these countries (Int$1,407) (3).  Costs and benefits are
shown in table 5.2.
Table 5.2: Costs and benefits of increased health expenditure 2002-2015 (2003 Int $)
Intervention Under-5
population
Total
benefit
(millions)
Total cost
(millions)
Net-
benefit
(millions)
Annualised
net-benefit
(millions)
BCR
Increased overall public
spending on health in
HIPC group (Int$ 1,470)
27,541,139 $874,492 $225,155 $649,376 $49,952 3.9
Calculated from (117) and (3)
                                                
22 These countries included: Bolivia, Burkina Faso, The Gambia, Honduras, Madagascar, Mali,
Mauritania, Mozambique, Niger, Rwanda, Senegal, Tanzania, and Uganda.
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If a 6% discount rate is used, ANB falls to Int$595,437 million, with a BCR of 4.36.  If
the ceiling ratio is increased to Int$3,830, ANB increases to $2,155,472 million, with a
BCR of 10.6.
Results are highly sensitive to the trend of baseline mortality used to calculate deaths
averted.  If it is assumed that the annual decreases in child mortality (1.1%) that
occurred in the developing world during the 1990’s continue to 2015 in the absence of
intervention (122), averted mortality is so reduced that total net-benefit becomes
negative (-Int$7.3 billion) (though it should be noted that if this trend does indeed occur,
a greater than two third reduction in child mortality might be expected from increased
expenditure).
In interpreting these figures, several points should be noted.  On the expenditure side,
the calculations assume an overall expansion in current patterns of health expenditure.
To the extent that expenditures can be better targeted, on high return health
interventions and on individuals with the worst health status, the returns are likely to be
higher.  Determinants of health other than expenditure, such as improvements in
education and level of consumption, are not considered and are likely to have a
synergistic impact.  On the benefit side, the effects of the expenditure increase on child
deaths only is included, although service expansion would be expected to benefit a
range of population groups.  Overall, the cohort of highly-indebted countries in the
analysis is expected to produce a modest estimate of the returns to investment.  Health
systems in financially-constrained countries are notoriously weak, and are likely to
require proportionally more investment to scale up health services than wealthier ones.
Package of priority interventions
Bobadilla and colleagues (1994) estimated that the WDR  package would cost Int$65
per person in low and middle income countries and would reduce the disease burden by
25%.  Based on 2002 estimates from the Global Burden of Disease database, this
package would be expected to avert 227,456,368 YLLs each year.  The economic
benefits of implementing such a package are outlined in Table 5.3.
Table 5.3: Costs and benefits of the 1993 World Development Report Package (2003 Int$)
Population Annual
Benefits
(millions)
Annual
Costs
(millions)
Annual net-
benefit
(millions)
BCR
Low and middle income
countries (Int$3,830)
909,825,472 $871,158 $337,073 $534,084 2.6
Figures based on (118) and (3)
The favourable benefit-cost ratio is expected as the framers of this package selected
clusters of interventions with strong consideration of their cost-effectiveness, targeted
towards groups that were most likely to benefit.  By clustering interventions and
including those with synergies between them, costs were kept to a minimum.  Applying
a standard ceiling ratio has no effect since the ceiling ratio is already that for low and
middle income countries.
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5.5 Feasibility
The growing literature on the relationship between public expenditure on health care
and health outcomes (115, 117) cautions against easily assuming that increased public
expenditure will be translated into improved health outcomes.  Analysis of the
relationship between public spending and child mortality finds results varying from
statistical significance to insignificance (5), for a variety of both methodological and
policy-related reasons.  With respect to the latter, public spending may not be well
targeted on the poor who have the worst health outcomes; much of it may not reach the
local service provider, being tied up at higher levels and in central hospitals; and service
quality is often very poor.  Failings may both be a reflection of the overall poor quality
of the policy environment, and of more mundane difficulties in managing service
provision in settings with very limited capacity, difficult communications, and few
trained staff.
The challenge of meeting the MDGs has lead to a recent focus on the difficulties facing
health service delivery, and on the constraints that need to be overcome to scale up the
coverage of priority health services (1) (123) (5).  This body of work directly addresses
the managerial challenges in strengthening basic health services. Although evidence is
still quite limited on how best to address constraints (124), it is good enough to make
some suggestions on how best to improve health services, both in the most highly
constrained countries (for example, those with very weak governments) and those which
are somewhat less constrained.  Table 5.4 both identifies constraints by level, and
suggests measures to address constraints in settings which are more or less constrained.
A key difference between these settings is that the weaker the government system, the
greater needs to be the reliance on working outside government channels, using NGOs
and the private sector, for example.
Table 5.4 Relaxing constraints: priority actions by type of country
Level of constraint        Highly constrained countries        Least constrained countries
Community and
household level
• Encourage community mobilization through
NGOs
• Use social marketing and retail sector to make
effective drugs available to households
• Use incentives to stimulate
demand
Health services
delivery level
• Build up health care delivery infrastructure
through public services and/or agreements
with NGO and church providers
• Use outreach services and NGOs where public
sector difficult to extend
• Improve human resource
management policies in
order to ensure better staff
performance
• Strengthen local
management
Health sector policy
and strategic
management level
• Increase degree of management
decentralization
• Strengthen drug supply and distribution system
through public and/or private sector
• Greater donor coordination
• Increase degree of
management decentralization
• Greater donor coordination
• Strengthen regulation of
private sector
Public policies
cutting across
sectors
• Give greater autonomy to
health sector
Environmental
characteristics
• Prepare for possible scale up under improved
conditions; maintain links with NGOs; support
education and training
• Encourage more pluralist
policy process
Source: (1)
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However, there are also issues of political and financial feasibility.  At international
level, there has been reluctance to envisage support to a health service development
strategy.  Political commitment appears to be easier to gain for specific disease control
efforts, such as HIV/AIDS and malaria.  It may be, however, that the current
international focus on extending anti-retroviral treatment to AIDS patients will help
change this attitude, since of all priority interventions, ARV treatment is highly
dependent on a health service infrastructure.  The importance being given to improving
service delivery and ensuring it serves the poor is indicated by its choice as the subject
of the WDR 2004 (5), which emphasises institutional changes to strengthen
relationships of accountability between policy makers, service providers, and citizens,
as the key to improving service delivery.
Financially, this opportunity faces the most severe financial constraints, since it is the
most costly of all three opportunities.  There is substantial disagreement over how much
countries need to spend to achieve high levels of coverage of priority interventions.  The
total annual costs estimated for the WDR 1993 package were $12 per capita in low
income countries and $22 per capita in middle income countries (US$ 1993).  The
Better Health in Africa cost was $13 per capita in low income African countries (125).
The CMH report put great stress on adequately costing the full cost of scaling up,
including adequate remuneration to health staff, expansion of training, and management
and supervisory capacity at all levels.  It also included a more extended AIDS package,
including treatment.  It estimated a total of $38 per capita ($2002) for low income
countries ($41 for least developed countries), to achieve the scaling up targets (17).
This level of expenditure implies on average 5.9% of GNP devoted to health (11.4% for
least developed countries), consisting of 2002 total health expenditure, plus the
additional costs of raising coverage and quality.  It can be noted that the CMH figure for
least developed countries is consistent with Gupta et al above, who estimated 12%.  The
CMH report estimated that donor aid to less developed countries would need to rise by
an additional $31 billion a year by 2015, if these country expenditure levels were to be
achieved (17).
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6 Discussion and conclusion
This paper has reviewed the evidence on the economic benefits of good health,
specifically in relation to communicable disease, and the economic costs of malaria and
HIV/AIDS.  It has also sought to estimate the benefits and costs of reducing the burden
of communicable disease, considering separately malaria control, HIV/AIDS control,
and scaled up basic health services.  In order to do this, evidence was drawn from four
main sources: macroeconomic studies of the economic cost of disease; microeconomic
studies of the costs and health effects of health interventions; estimates of the efficiency
of health expenditures with respect to health outcomes; and examples of successful
programmes where some data were available on costs and health benefits.
All these sources of data have substantial shortcomings, which must inform the
interpretation of the estimates of costs and benefits.  In particular:
• The macroeconomic literature is quite inadequate.  In the case of malaria, it is very
sparse (2 recent studies only) and has yet to generate a critical debate on methods
and data.  In the case of HIV/AIDS, the literature provides wildly differing
estimates, ranging from minimal impact on per capita income to a massive impact.
• The microeconomic literature relates largely to interventions implemented
individually in the context of epidemiological trials; evidence of costs and health
effects in the context of large scale programme implementation is very limited.
Furthermore, health effects have to be translated into a monetary value.  We chose
to apply the ceiling ratio of one times per capita GNI, but this decision is arbitrary;
in sensitivity analyses we applied the GNI for low and middle income countries in
order not to disadvantage health gains in poor countries.
• The analysis of the efficiency of health expenditure relates all health expenditure to
health outcomes for a single population group, omitting benefits for others.
• Evidence from successful programmes is hard to interpret, since external factors
may also have affected changes in health effects.
Macroeconomic estimates of benefits and calculations made from cost-effectiveness
evidence cannot of course be assumed to be reflecting the same dimensions of benefits.
Macroeconomic benefits allow for interactions over time, where improved health feeds,
for example, into increased labour supply quantity and quality, and into changed savings
and investment patterns.  In contrast, the conversion of health gains into a monetary
value reflects an assumption on the value of human life, not necessarily related to its
productive potential.  Moreover, given the weakness of the evidence base, it would be
unwise to read too much into differences between the evidence from these two different
sources.
In addition, our estimates suffer from other shortcomings:
• We would have preferred to have estimated costs and benefits over the same time
periods, and discounted to present values or calculated an internal rate of return.
Given the varied nature of the available data, this was not possible to do consistently
• Available costs were usually costs to the provider, excluding costs to users
• Savings in health care costs that would result from preventive activities were rarely
included in the estimates
• We would have liked to have been more explicit on who would benefit under each
of the challenges, and in particular on the extent to which the poorest would benefit.
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This is partly a question of which groups suffer most from the diseases in question,
and partly an issue of the extent to which countries are able or willing to ensure that
all population groups benefit from expanded disease control efforts.
This last point bears on the feasibility of the opportunities considered.  Increased health
expenditure will be translated into improved health outcomes only if the right policies
are adopted and well implemented.  Low and middle income country health systems
often have shortcomings, which mean that they are less efficient at transferring
expenditure into health gains than they could be.  Thus considerable attention has to be
paid to the structures through which health programmes are implemented, as well as to
the preferences and knowledge of users.  Moreover, the focus of two of the challenges
on controlling specific communicable diseases should not be interpreted to indicate that
their implementation can avoid the problems and inefficiencies of working through
existing health systems.  As made clear in the text, important components of both
malaria and HIV/AIDS control are dependent on the health system.
Given all these caveats, we highlight and summarise our estimates in Table 6.1. A
complete summary of all results is in the Annex.  On the basis of the earlier analyses,
we have selected a subset of results to include, based on criteria of :
• relevance to a range of countries
• inclusion of a package of interventions.
It should be noted that the per capita costs apply to different populations; in some cases
the general population and in others the target groups for particular interventions (as
noted in the relevant column).  The last two columns show the results of the sensitivity
analysis on the DCR and ceiling ratio in terms of its impact on the BCR.
The table suggests that many health interventions and programmes are highly cost
beneficial.  There is a general pattern, as one might expect, that estimates based on cost-
effectiveness data for specific interventions (packages of malaria and HIV
interventions) show much higher benefit cost ratios than broader programmes.   At least
in part this is for methodological reasons – for example underestimation of the
necessary costs of system strengthening, and likely overestimation of benefits because
of drawing evidence of effectiveness from trial data.  However, it is noteworthy that the
real life example, that of HIV prevention in Thailand, shows substantial net benefits and
a favourable BCR of 15.   The WDR package has the highest net benefits of all (partly
because it is applied to all low and middle income countries) and a favourable benefit
cost ratio, of 2.6.  The estimate based on Gupta et al also has a favourable benefit cost
ratio, of 3.9, despite three factors that might be expected to reduce it: the costs relate to
increasing health expenditure overall but the benefits were estimated for child mortality
only (excluding benefits in adult health); the increase in health expenditure represents
an increase in the overall pattern of health expenditure, not the targeting to effective
interventions; the countries in the analysis are some of the poorest, where it might be
expected that the costs of achieving a given health effect are higher given the multiple
disadvantages faced by their populations.  However, the estimate is highly sensitive to
assumptions on the underlying rate of child mortality change.
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Table 6.1: Summary of key results (Int$ 2003)
Opportunity, Source,
Geographic Region
Per-capita
costs
(annualised)
Total benefit
(annualised,
millions)
Total cost
(annualised,
Millions)
Net-benefit
(annualised,
millions)
BCR
3%
DCR
BCR
6% DR
BCR
Rc =
Int$3,830
Control of malaria
Based on evidence from
macroeconomic models
$21 per person $22,996 -
$55,359
$11,873 $11,123 -
$43,486
1.9 -
4.7
1.8 -
4.3
no ceiling
ratio
Package of malaria
interventions
$50,417 $2,942 $47,375 26.9 24.7 59.5
Control of HIV/AIDS
Thai programme of prevention $28.92 per
case averted
$3,704 $248 $3,455 14.9 15.1 9.2
Package for prevention of
HIV/AIDS. Six regions (EAP,
EAC, LAC, SEA, SAR, SSA)
$11.36 per
person
$366,769 $7,345 $359,423 49.9 DCR
within
model
42.9
Scaled up basic health services
Increased health expenditure.
13 Highly Indebted Poor
Countries
$106.89 per
child
$67,269 $17,317 $49,952 3.9 4.4 10.6
WDR (1993) Minimum
package. Low and Middle
Income Countries
$65 per person $871,158 $337,073 $534,084 2.6 One
year
2.6
Despite uncertainties over the estimates, the table emphasises that there are likely to be
high returns from investing in communicable disease control – benefit cost ratios
substantially exceeding one.  Taken with the currently low coverage of malaria,
HIV/AIDS and basic health care programmes in large parts of the developing world,
especially SSA, they suggest that communicable disease control is substantially under-
resourced.  Moreover, investments where health status is low will provide substantial
benefits to the poorest populations of the world.
It remains uncertain whether greater returns are achievable from a focused effort to
address specific diseases, such as malaria or HIV/AIDS, or from a broader basic health
services strategy.  However it cannot be emphasised enough that these three approaches
are not completely independent – both malaria and HIV/AIDS control must include a
substantial component of strengthening basic health services if they are to be successful.
While costing sought to allow for this, it is probable that the system strengthening costs
required for malaria and HIV specific interventions have not been adequately allowed
for, suggesting that in practice there may be less of a difference between disease
specific interventions and general health service interventions than suggested in the
table.
For reasons of space and focus, this paper has not explored issues of the role of
government in addressing communicable disease.  However, a strong case can be made
for public funding for controlling communicable diseases, on both poverty and
efficiency grounds (given positive externalities and public goods arguments).
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Finally, it should be noted that the productivity of health expenditure is likely to be
greater both in a supportive policy environment, and where complementary investments
take place, such as in female education.
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ANNEX: Complete summary of results (Int$ 2003)
Opportunity,
Source,
Geographic
Region
Per-capita costs
(annualised)
Total annual
benefit (m)
Total annual
cost
(m)
Annual net-
benefit (m)
BCR BCR
6% DR
BCR
Rc =
$3,830
Control of malaria
Based on macroeconomic models
Gallup & Sachs
2001); Jha and
Mills (2002)
$21 per
person
$55,359 $11,873 $43,486 4.7 4.3 no
ceiling
ratio
McCarthy et al
(2000); Jha and
Mills (2002)
$21 per
person
$22,996 $11,873 $11,123 1.9 1.8 no
ceiling
ratio
ITNs for children under 5, Goodman et al. (2000)
SSA – LIC $28.47 per
child
$6,694 $1,180 $5,513 5.7 5.4 25.6
SSA – MIC $29.02 per
child
$5,308 $435 $4,873 12.2 11.5 25.1
SSA – HIC $33.50 per
child
$6,477 $158 $6,319 41.1 39.1 21.7
SSA – Total $30.33 per
child
$18,479 $1,773 $16,706 10.0 9.5 25.1
IPTp at ANC visits, Goodman et al. (2000)*
SSA – LIC $6.59 per PG $174 $22 $152 8.0 7.5 36.1
SSA – MIC $7.29 per
PG
$138 $9 $129 15.9 14.8 32.6
SSA – HIC $12.47 per
PG
$168 $5 $164 36.1 34.0 19.1
SSA – Total $8.78 per PG $480 $35 $445 12.1 11.3 33.9
Switch from SP to ACTs, Coleman et al. (2004)*
SSA 2.98 per
malaria case
$19,331 $501 $18,830 38.6 34.3 84.5
Scaling up ACTs, Coleman et al. (2004)*
SSA 20.21 per
malaria case
$12,130 $634 $11,496 19.1 19.1 41.9
Switch from SP to ACTs in South Africa
Muheki et al (2004) -$98.37 per case
averted
$0.1 -$0.4 $0.5 Cost-
saving
no DCR Cost-
saving
Control of HIV/AIDS
Based on macroeconomic models. Robalino (2002)
Algeria n/a n/a n/a $1,525 n/a n/a n/a
Egypt n/a n/a n/a $2,444 n/a n/a n/a
Iran n/a n/a n/a $3,003 n/a n/a n/a
Jordan n/a n/a n/a $116 n/a n/a n/a
Lebanon n/a n/a n/a $121 n/a n/a n/a
Morocco n/a n/a n/a $788 n/a n/a n/a
Tunisia n/a n/a n/a $712 n/a n/a n/a
Yemen n/a n/a n/a $12 n/a n/a n/a
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Opportunity,
Source,
Geographic
Region
Per-capita costs
(annualised)
Total annual
benefit (m)
Total annual
cost
(m)
Annual net-
benefit (m)
BCR BCR
6% DR
BCR
Rc =
$3,830
Country experience
Thailand
programme, Brown
(2003)
$28.92 per case
averted
$3,704 $248 $3,455 14.9 15.1 9.2
Specific interventions, Creese et al (2002) sub-Saharan Africa
Condom
distribution
n/a n/a n/a n/a 466 - 5 n/a 1,019 -
10
Blood safety n/a n/a n/a n/a 466 -
11
n/a 1,019 -
24
Peer education for
sex workers
n/a n/a n/a n/a 116 -
67
n/a 255 -
146
Prevention of MTC
transmission
n/a n/a n/a n/a 52 - 1 n/a 113 -
1.39
Treatment of STIs n/a n/a n/a n/a 39 n/a 85
VCT n/a n/a n/a n/a 26 - 21 n/a 57 - 46
Short course
treatment, TB
n/a n/a n/a n/a 233 - 7 n/a 509 - 15
Co-trimoxazole
prophylaxis
n/a n/a n/a n/a 78 n/a 170
Home care n/a n/a n/a n/a 6 - 0.4 n/a 13 - 0.8
Tuberculosis
preventive therapy
n/a n/a n/a n/a 3 - 2 n/a 6 - 3.5
ARV n/a n/a n/a n/a 0.4 -
0.3
n/a 0.9 - 0.6
Package for prevention of HIV/AIDS, Stover et al (2002)
Six regions (EAP,
EAC, LAC, SEA,
SAR, SSA)
$11.36 per
person
$366,769 $7,345 $359,423 49.9 DCR
within
model
42.9
Scaled up basic health services
Increased health
expenditure, HPIC,
Gupta (2001)
$106.89 per
person
**$67,269 $17,317 $49,952 3.9 4.4 10.6
WDR (1993)
Minimum Package,
Low and Middle
Income Countries
$65 per
person
$871,158 $337,073 $534,084 2.6 One
year
2.6
Abbreviations: MTC: mother-to-child transmission;  VCT: voluntary counselling and testing; STIs: sexually transmitted infections;
ARV: anti-retroviral therapy;  LIC: low income countries; MIC middle income countries; HIC higher income countries; IPT(p):
intermittent treatment of pregnant women; SP: Sulfadoxine-pyrimethamine; PG: primigravidae (first pregnancy); ACT:
artemisinin-based combination therapy; WDR: World Development Report
*Adapted from original study
** gains in child health only included
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